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DioxygenaseThe 2,4-diaminoquinazoline class of compounds has previously been identiﬁed as an effective inhibitor of
Mycobacterium tuberculosis growth. We conducted an extensive evaluation of the series for its potential as
a lead candidate for tuberculosis drug discovery. Three segments of the representative molecule
N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine were examined systematically to explore
structure–activity relationships inﬂuencing potency. We determined that the benzylic amine at the
4-position, the piperidine at 2-position and the N-1 (but not N-3) are key activity determinants. The
3-deaza analog retained similar activity to the parent molecule. Biological activity was not dependent
on iron or carbon source availability. We demonstrated through pharmacokinetic studies in rats that
good in vivo compound exposure is achievable. A representative compound demonstrated bactericidal
activity against both replicating and non-replicating M. tuberculosis. We isolated and sequenced
M. tuberculosismutants resistant to this compound and observed mutations in Rv3161c, a gene predicted
to encode a dioxygenase, suggesting that the compound may act as a pro-drug.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is an
infectious disease for which there is still a great need for discovery
and development of novel drugs to improve therapy.1 In 2010
alone, the World Health Organization reported 8.8 million new
cases and 1.4 million deaths from the disease.2 In addition, billions
of people harbor latent infections with no clinical symptoms, but
with the potential to advance to active form. Current TB treatment
requires a combination of four drugs, isoniazid (INH), rifampicin
(RIF), pyrazinamide (PZA), ethambutol (ETH) for 2 months fol-
lowed by an additional 4 months of INH and RIF. These drugs have
been in use for many decades, contributing to a rise in the emer-
gence of multidrug resistant (MDR) and extensively drug-resistant
(XDR) strains of M. tuberculosis. New drugs are needed urgently to
shorten the duration of therapy and to treat drug-resistant strains.Diaminoquinazolines (DAQ) have been reported with activity
against a diverse range of biological diseases including lupus,
rheumatoid arthritis, malaria and hypertension.3 The DAQ series
is active against M. tuberculosis4 and effective at preventing the
growth of M. tuberculosis5 with minimum inhibitory concentra-
tions (MICs) reported in the range of 1.3–6.1 lg/mL. The DAQ
series is less effective against other bacterial species, with weak
activity against Escherichia coli and Pseudomonas aeruginosa,
suggesting some element of selectivity.6
We were interested in the potential of the DAQ series as a
starting point for drug discovery. We conducted an exploratory
study to evaluate the potential of the series for progression as a
drug lead molecule.
2. Results and discussion
To investigate the biological activity, and the pharmaceutical
and pharmacokinetic (PK) properties of the DAQ class of com-
pounds, we conducted a systematic structural modiﬁcation of a
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Scheme 1. Synthesis of 2,4-substituted quinazolines. Reagents and conditions: (a) X = R1: Cl3CCOCl, DMAP, CH2Cl2; (b) NH4OAc, DMSO; (c) (i) POCl3, (ii) Piperidine, i-PrOH,
reﬂux; (d) X = OH: KOCN, NaOH; (e) X = NH2: phosgene; (f) POCl3, NN-dimethylaniline, reﬂux; (g) (i) nucleophile (R2XH: X = O,S,NH), THF, room temperature, (ii) R3R4NH, i-
PrOH, reﬂux; (h) X = OH: R5CONH2, HCO2H (i) 4-ﬂuorobenzylamine, THF, room temperature.
Table 1
Effect of C-2 and C-4 substitutions on biological potency of DAQ
N
N
R
N
4-35
N
N
HN
R
7, 36-61
F
Compd R-group MIC I Compd R-group MIC I
4 PhCH2HN- 9.2 96 34 H- 469 <30
5 2-FPhCH2HN- nd 97 35 4-FPhCH2CH2- nd <30
6 3-FPhCH2HN- nd 98 7 Piperidin-1-yl 7.4 97
7 4-FPhCH2HN- 7.4 97 36 4-(CH3)piperidin-1-yl nd 97
8 3-MePhCH2HN- nd 99 37 4-(OH)piperidin-1-yl nd <30
9 3-IPhCH2HN- nd 98 38 4-(NH2)piperidin-1-yl nd <30
10 4-MePhCH2HN- nd 98 39 4-(NHMe)piperidin-1-yl nd 33
11 4-MeOPhCH2HN- nd 97 40 4-(NMe2)piperidin-1-yl nd <30
12 4-OCF3PhCH2HN- nd 95 41 4-(CO2H)piperidin-1-yl nd <30
13 4-ClPhCH2HN- nd 99 42 3,5-(Me)piperidin-1-yl nd <30
14 4-CF3PhCH2HN- 6.6 99 43 4-(CH2OH)piperidin-1-yl nd <30
15 4-NH2PhCH2HN- nd <30 44 4-(NHCH2CO2H)piperidin-1-yl nd <30
16 2,4-FPhCH2HN- nd 97 45 2-(CH2CO2H)piperidin-1-yl nd <30
17 3,4-FPhCH2HN- nd 96 46 H2N- 93 <30
18 2,4-ClPhCH2HN- nd 98 47 MeHN- 35 44
19 3,4-ClPhCH2HN- nd 98 48 Me2N- 34 40
20 2,5-ClPhCH2HN- nd 97 49 Pyrrolidin-1-yl 31 97
21 3-Cl, 4-MeOPhCH2HN- nd 98 50 Isoindolin-2-yl nd 78
22 4-FPhCH2O- 296 <30 51 Piperazinyl 148 <30
23 4-FPhCH2S- 282 <30 52 4-(4-Anilinyl)piperazin-1-yl nd 94
24 MeHN- 206 <30 53 (HOCH2CH2)2HN- nd <30
25 iPrHN- 25 37 56 (Piperidin-1-yl)CH2HN- 29 <30
26 cyclohexylCH2HN- nd 99 57 H- 99 <30
27 4-CF3PhCH2CH2HN- 5.7 97 58 Me- 94 <30
28
H
N nd 97 59 F3C- nd <30
29 4-FPhHN- 39 <30 60 Ph- 76 <30
30 Piperidin-1-yl nd <30 61 Cyclohexyl- 15 47
31 N
F
nd 94 Rifampicina 0.013/0.004 100
Compounds were tested for inhibition of M. tuberculosis in liquid and on solid medium. The percent inhibition (I) of growth at 20 lM in liquid medium is reported.
Compounds were considered inactive if %I <30 at 20 lM. Minimum inhibitory concentrations (MIC) were determined using the serial proportion method on solid agar.
a MIC reported for solid/liquid medium. nd = not determined.
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Table 2
Effect of core replacement on biological potency
N
N
HN
N
62-75
F
R1
R2
Compound R1, R2 MIC I
Rifampicina 0.013/0.004 100
62 H, Me 83 <30
63 Me, H 83 <30
64 Me, Me nd <30
65 Benzyl, H 26 68
66 H, Benzyl 27 84
67
N
74 37
68
N
30 59
69
N
37 <30
70
S
73 nd
71
S
292 <30
72 N
H
nd <30
73 N nd <30
74 N
H
N
nd <30
75
N
N
nd <30
Compounds were tested for inhibition of M. tuberculosis in liquid and on solid
medium. The percent inhibition (I) of growth at 20 lM in liquid medium is repor-
ted. Compounds were considered inactive if %I <30 at 20 lM. Minimum inhibitory
concentrations (MIC) were determined using the serial proportion method on solid
agar.
a MIC reported for solid/liquid medium. Nd = not determined.
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4-amine (7). Analogs with key modiﬁcations to the piperidine
residue at C-2, the 4-ﬂuorobenzylamino residue at C-4 and the
quinazoline core structure were synthesized to provide structure
activity relationship (SAR) information. For each compound, the
biological activity (growth inhibition) was tested against M. tuber-
culosis in liquid medium; for selected compounds activity was also
tested on solid medium.
2.1. Exploration of C2 and C-4 substitutions
Several 2,4-diaminoquinazolines incorporating a single-point
variation at C-2-position (4–31) or C-4-position (36–53) of the qui-
nazoline template of the reference structure (7) were readily syn-
thesized according to Scheme 1, by the nucleophilic aromatic
substitution reaction on a key 2,4-dichloroquinazoline intermedi-
ate (3). The dichloroquinazolines were either purchased or pre-
pared from commercial quinazoline-2,4(1H,3H)-dione (2) by
chlorination with phosphorus oxychloride in N,N-dimethylaniline
under reﬂux conditions. Where necessary, the quinazolinediones
were prepared from corresponding anthranilamides (1) via conden-
sation with phosgene. Regioselective substitution of C-4 chloride in
3 with the appropriate amine was accomplished at room tempera-
ture. Nucleophilic substitution at C-2 with the second amine pro-
ceeded smoothly at higher temperatures in isopropanol or
tetrahydrofuran to give target compounds (4–31, 36–53).7 The C-
4 ether, 4-(4-ﬂuorobenzyloxy)-2-(piperidin-1-yl) quinazoline (22)
and the thioether, 4-(4-ﬂuorobenzylthio)-2-(piperidin-1-yl) qui-
nazoline (23) were similarly prepared utilizing the corresponding
sodium salt of benzyl alcohol or thiol as nucleophiles. Alternative
routes were adapted to incorporate different alkyl and aryl substit-
uents at these positions. The preparation of analogs 56–61, bearing
aliphatic or aromatic substituents at C-2 began with the condensa-
tion of anthranilamide with appropriate aldehydes, followed by
chlorination of the resulting 2-substituted quinazolin-4(3H)-one
(54) with phosphorus oxychloride to give key intermediates8,9
(55), which were readily converted to the 4-amino analogs 56–61.
The synthesis of analogs 34 and 35 bearing alkyl group at C-4 were
carried out using 2-aminophenones10 (1, X = alkyl) as the starting
point for similar condensation, chlorination and amination
sequence of reactions.
The biological activity for each compound was determined by
measuring inhibition of growth against a virulent strain of
M. tuberculosis in liquid medium (Table 1–3). In liquid medium
none of the compounds gave an MIC <20 lM, although most com-
pounds had activity, that is, >30% inhibition of growth at 20 lM
and could be ranked loosely based on this value. Several com-
pounds were tested for MIC on solid medium; surprisingly MICs
were lower than for liquid medium for several of the compounds
(4, 7, 14, 27), but a large variation was seen which was used to
inform the SAR analysis.
Aromatic substituents on the benzylamino residue had very lit-
tle or no inﬂuence on activity; analogs incorporating various sub-
stituents (F, Cl, Br, Me, OMe, NH2, CF3, OCF3) (5–21) all showed
comparable activities. However, the lipophilicity of the C-4 substi-
tuent seemed important as replacement of the benzyl with simple
groups such as hydrogen (34), methyl (24) or an isopropyl (25)
group, resulted in substantial reduction in the inhibitory activity.
On the other hand, similar lipophilic groups like the non-aromatic
cyclohexylmethyl (26) displayed good activity. The importance of
the amino function at C-4 was examined by replacement with an
ether (22), thioether (23) and methylene (35) units, all of which
resulted in complete loss of activity. The activities of a secondary
(tetrahydroisoquinoline, 31) and primary C-4 amine analogs were
comparable, precluding signiﬁcance of any hydrogen-bonding
contribution to activity. Homologation of the C-4 benzylaminogroup to a phenethylamino moiety (27) resulted in a very small
improvement in the inhibitory activity. The aniline derivative
(29) lacking any methylene spacer between the core and the lipo-
philic group was relatively less active.
2.2. Exploration of the core
We explored the core quinazoline structure through the
synthesis of analogs outlined in Schemes 2–4. All azaquinazoline
analogs (67–69) reported were easily prepared from their corre-
sponding 2,4-dichlorides in good yields. We were, however, unable
to prepare and isolate the 6-aza analog. Similarly, the thieno[2,3-
d]pyrimidine (70, 71), pyrrolo[2,3-d]pyrimidine (72, 73) and purine
(74, 75) analogswere prepared from corresponding dihalides. Other
quinazoline core replacement prepared include the quinoline ana-
logs (88, 89, 90) which were similarly prepared from 2,4-dichloro-
quinoline. The synthesis of pyrazolo[1,5-a]pyrimidine (94) and
triazolo[1.5-1]pyrimidine (95) analogs were achieved via a sequen-
tial diamination of their respective key dihalide (93)11 intermedi-
ates as illustrated in Scheme 3.
Table 3
Effect of core substitutions on biological potency
N
X
HN
N
7, 76-90
F
R1
R2
Compound R1 R2 X MIC I
Rifampicin 0.013/0.004a 100
7 H H N 7.4 97
76 5-F H N nd <30
77 8-NO2 H N nd <30
78 5-Cl H N nd <30
79 6-Cl H N nd 49
80 7-Cl H N nd 51
81 8-Cl H N nd <30
82 5-Me H N nd 98
83 6-Me H N nd 99
84 6-OMe H N nd 97
85 7-OMe H N nd 74
86 8-OMe H N nd 83
87 6,7-OMe H N 25 92
88 H H C nd 98
89 H CH2OH C nd 55
90 H CO2H C nd <30
94 — — — — <30
95 — — — — <30
103 — — — 27.7/13.8a 98
Compounds were tested for inhibition of M. tuberculosis in liquid and on solid
medium. The percent inhibition (I) of growth at 20 lM in liquid medium is repor-
ted. Compounds were considered inactive if %I <30 at 20 lM. Minimum inhibitory
concentrations (MIC) were determined using the serial proportion method on solid
agar.
a MIC reported for solid/liquid medium. nd = not determined.
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tion against a virulent strain of M. tuberculosis in agar and liquid
medium (Table 2). Compounds had activity in both liquid and solid
medium. Among the various C-2 substituents synthesized,N
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Scheme 2. Synthesis of DAQ derivatives with variation in the benzo region. Reagents an
N,N-dimethylaniline, reﬂux; (d) (i) 4-ﬂuorobenzylamine, THF, room temperature, (ii) pippiperidine remained a preferred residue (7) at this position. Pyrrol-
idine homologs (49, 50) were also accommodated with no loss in
activity. Piperazine substitution (51) resulted in complete loss of
activity, but all activity was regained with an N-40-aromatic substi-
tuted piperazine (52). Smaller, non-cyclic amines (46–48, 53)
showed greater than two-fold reduction in activity. Non-amine
substitution such as alkyls or aryls (56–61) resulted in loss of activ-
ity with cyclohexyl analog (61) showing the least, a two-fold,
reduction. We also investigated variously substituted piperidines
(36–45) at the C-2 position for SAR exploration and for physico-
chemical property modulation. In general, substitution on the C-2
piperidine was detrimental to anti-TB activity.
The results also indicated that the benzo portion of this core is
important to anti-TB activity. This was inferred from the very weak
biological activity of core replacement analogs such as the substi-
tuted pyrimidine derivatives (62–66), thiophenopyrimidines (70–
71), the diazaindoles (72–73) and purine analogs (74, 75). A change
to an azaquinazoline core (67–69) was tolerated but with relatively
weaker activity compared to the parent quinazoline. To explore the
role of the quinazoline ring nitrogens, we prepared and tested the
analogous quinoline analogs (88–90). The retention of activity for
this core indicated a non-essentiality of N-atom at N-3 position
which prompted us to investigate other analogs based on this core.
The pyrazolo[1,5-a]pyrimidine (94) and triazolo[1.5-1]pyrimidine
(95) analogs, synthesized as representative extension of this core
were essentially inactive but an imidazoquinoline derivative
(103) displayed moderate activity.
Substitutions at the C-5, C-6, C-7, and C-8 positions of the qui-
nazoline core followed a general pattern inwhich electron-donating
substituents (82–87) retained activity while electron-withdrawing
groups had a negative impact (76–81).
2.3. Other analogs
We prepared a number of scaffold analogs that incorporated
changes at N-atom at position-3. The imidazoquinoline derivative
(103) was prepared from commercial 3-nitroquinolin-4-ol (96)
according to Scheme 4.12 Chlorination of 96 with phosphorus oxy-
chloride inN,N-dimethylformamide gave 3-nitro-4-chloroquinolineN
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Scheme 4. Synthesis of an imidazoquinoline derivative. Reagents and conditions: (a) POCl3, DMF, heat; (b) 4-ﬂuorobenzylamine, EtOH, Et3N; (c) 5% Pt/C, H2, ethyl acetate; (d)
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Figure 1. The representative DAQ exhibits bactericidal activity. Kill kinetics of M.
tuberculosis by 14 in aerobically growing cells (squares) and under starvation
conditions (triangles). For the aerobic kill curve, cells were inoculated to a starting
OD590 of 0.01 into 7H9/OADC containing 124 lM of 14 and CFU/mL were
enumerated at indicated time points. For the starvation-kill curve, cells were
harvested at mid-log phase, re-suspended in phosphate buffered saline to an OD590
of 0.01 and maintained for 2 weeks at 37 C. Compound 14was added (124 lM) and
CFU/mL determined at indicated time points following compound addition. The
limit of detection was 10, as indicated by the dotted line.
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Figure 2. DAQ inhibit growth of M. tuberculosis under iron-excess conditions. Cells
were inoculated to a starting OD590 of 0.04 into growth medium containing no
compound 14 (circles), 28 mM compound 14 (triangles) and 56 mM compound 14
(squares). Growth was monitored in the presence (solid symbols) and absence
(open symbols) of 40 mg/mL hemin supplementation.
J. Odingo et al. / Bioorg. Med. Chem. 22 (2014) 6965–6979 6969(97) whichwas subsequently subjected to nucleophilic substitution
of the chloride by 4-ﬂuorobenzylamine to furnish N-(4-ﬂuoroben-
zyl)-3-nitroquinolin-4-amine (98). Catalytic reduction of 98 led to
the diamine derivative 99, a precursor to the imidazoquinoline
(100). The imidazoquinoline, prepared via condensation of 99 with
reﬂuxing triethyl orthoformate, was oxidized with peracetic acid
to its N-oxide (101), and then chlorinated to provide the chloroimi-
dazoquinoline (102). Finally, 102 was reﬂuxed with piperidine in
N,N-dimethylformamide to provide the target compound, 1-(4-ﬂuo-
robenzyl)-4-(piperidin-1-yl)-1H-imidazo[4,5-c]quinoline (103).
2.4. The DAQ series show bactericidal activity
In order to probe the biological proﬁle of the DAQ series, we
conducted a number of additional microbiological assays. We
selected compound 14 since it had relatively good activity in solid
assays with an MIC of 6.6 lM. The most active compound (14) was
tested for bactericidal activity in aerobic, replicating culture and
under non-replicating conditions generated by nutrient starvation
(Fig. 1). Interestingly, compound 14 was bactericidal against M.
tuberculosis under both conditions. In aerobic culture a loss of 40 2 4 6
0.0
0.5
1.0
1.5
2.0
Days
O
D
59
0
Figure 3. DAQ inhibition ofM. tuberculosis is not dependent on carbon source. Cells
were inoculated to a starting OD590 of 0.04 into growth medium containing no
compound 14 (circles), 14 mM compound 14 (triangles) and 28 mM compound 14
(squares). Growth in medium containing palmitic acid (solid symbols) was
compared to that containing OADC (open symbols) supplement.
Table 4
Pharmacokinetic parameters for DAQs following a single 10 mg/kg oral gavage dose in rats
Compd MW CLogP (day) NV PSA VDss (L/kg) CL (mL/min/kg) PO AUC (ng*hr/mL) Bioavail (%F)
7 336.41 5.05 41.1 12.2 ± 2.7 115 ± 21 245 ± 66 16.7 ± 3.3
21 382.89 5.45 50.3 9.3 ± 1.0 133 ± 16 132 ± 20 10.3 ± 1.3
24 242.32 3.46 41.1 5.7 ± 0.6 179 ± 13 209 ± 134 21.8 ± 13.0
34 213.28 2.65 29 4.5 ± 0.2 153 ± 9 196 ± 82 17.6 ± 6.3
36 350.44 5.57 41.1 25.7 ± 18.3 179 ± 79 171 ± 32 21.7 ± 14.0
44 409.46 0.606 90.4 5.0 ± 1.2 99.2 ± 18.7 0.84 ± 0.89 0.05 ± 0.05
46 268.29 3.46 63.8 13.3 ± 0.2 154 ± 25 376 ± 48 34.0 ± 0.7
47 282.32 4.29 49.8 9.2 ± 1.0 95.3 ± 7.7 1610 ± 247 92.2 ± 18.9
48 296.35 4.38 41.1 8.1 ± 1.0 85.5 ± 11.6 1310 ± 339 65.9 ± 12.4
62 300.38 4.17 41.1 12.8 ± 0.9 131 ± 21 82 ± 16 6.4 ± 0.3
103 360.43 5.05 34 14.2 ± 6.2 201 ± 26 27.4 ± 6.5 3.4 ± 1.0
Compounds were administered to rats with a single oral dose of 10 mg/kg. Concentrations in plasma were determined at various time points over 24 h and pharmacokinetic
parameters calculated using Watson (version 7.4; Thermo Fisher Scientiﬁc). Clearance (CL), volume of distribution (VDss), area-under-the-curve (PO AUC) and bioavailability
(%F) are given. Molecular weight (MW); Calculated partition coefﬁcient (C logP, daylight software); Topological polar surface area (TPSA, novartis software) are also given.
Table 5
DAQ resistance results from mutations in the putative dioxygenase, Rv3161c
Strain Compound 14 solid MIC (lM) Rv3161c mutation
H37Rv 6.6 N/A
RM1 25 IS6110 at nt 801
RM2 25 GT deletion at 175–176
RM7 25 C115W
Comparison of wild-type (H37RvLP) and 3 spontaneous resistant mutants to
compound 14. Solid MIC (mM) values to Compound 14 are indicated. Whole gen-
ome sequencing indicated that all three resistant strains contain mutations in
Rv3161c as shown. RM: resistant mutant. N/A: not applicable. nt: nucleotide.
6970 J. Odingo et al. / Bioorg. Med. Chem. 22 (2014) 6965–6979log viability was seen over 7d and similarly 3 logs of kill was seen
over 7 days under starvation conditions.
2.5. Lack of iron chelating activity
The amine at the C4 position has the potential to form a chelat-
ing center with the N3 of the core, although it would be weak.
Therefore, we considered the possibility that the compound might
act via chelation of iron in cultures leading to an intracellular iron
shortage. To test this possibility, we monitored growth in liquid in
the presence of hemin to supply additional iron to the cells, since
we already knew that hemin was transported intoM. tuberculosis.13
Under these conditions 56 lM of compound 14 was sufﬁcient to
prevent growth completely, regardless of hemin supplementation
(Fig. 2). These data suggest that it is unlikely that the compound
acts via iron chelation, in agreement with the structural features
of 14 which are devoid of any signature chelation motifs.
2.6. Carbon source dependency
Previously published data suggested that the DAQ series as a
class of compounds had signiﬁcantly lower MICs in liquid medium
than those we found.5 One of the major differences in the method-
ology for determining MIC was the carbon source in the growth
medium, in our case the simple sugar glucose, as opposed to the
fatty acid palmitate (hexadecanoate). Since the catabolic pathways
for utilizing these carbon sources differ, it is possible this altered
metabolism might be reﬂected in different MICs. We determined
whether compound potency was carbon source-dependent using
the same strain of M. tuberculosis. Growth was monitored in liquid
medium and the MIC was determined on solid medium. No differ-
ence was seen, with the liquid MIC of 28 lM in both growth media,
and the solid MIC of 16 lM (Fig. 3). Thus we discounted the possi-
bility that the potency of the compound series is dependent on the
carbon source.
2.7. Evaluation of pharmacokinetic properties in rats
To determine the in vivo exposure a set of twelve compounds
was selected and evaluated for pharmacokinetic (PK) properties
in rats (Table 4). The selection was guided by a multiparameter
analysis of all compounds. Calculated compound properties taken
into consideration included lipophilicity (C logP), distribution
coefﬁcient values at pH = 7.4 (C logD), molecular weight (MW),
topological polar surface area (TPSA), number of hydrogen bond
donors (HBD) and acidity/basicity parameter (pKa).
Sprague-Dawley rats were administered a single dose of the test
compound either iv at 1 mg/kg or orally at 10 mg/kg (Table 4). Thevolume of distribution was generally high for all compounds.
Plasma clearance was rapid for all compounds and the absolute
oral bioavailability was moderate (10–35%) for most compounds
tested. However, two structurally similar analogs, 47 and 48, were
well-absorbed with bioavailability of 92% and 66% (%F), respec-
tively. The carboxylate analog, 44, registered the poorest oral expo-
sure, presumably due to slow, passive permeability as a result of
the high polarity conferred by the amino carboxylate and a drasti-
cally reduced lipophilicity (C logP = 0.6).
2.8. Resistant mutant isolation for target identiﬁcation studies
Drug resistance in M. tuberculosis is largely mediated by chro-
mosomal mutations. For example, mutations may modify the drug
target, inactivate bacterial enzymes that activate pro-drugs, lead to
decreased membrane permeability, or up-regulation of efﬂux
pumps. To ascertain the mechanism(s) responsible for resistance
to 14 we isolated spontaneous resistant mutants to this compound
and analyzed 3 resistant mutants by whole genome sequencing.
Resistant mutants were isolated which showed a four-fold shift
towards resistance to compound 14. We sequenced the entire gen-
ome in order to identify single nucleotide polymorphisms. In all
three cases, mutations were observed in Rv3161c, a non-essential
and poorly characterized gene predicted to encode a dioxygenase
(Table 5). We observed an insertion of the transposable IS6110
element and a 2 base pair deletion which should both result in
gene inactivation. The third mutation results in the substitution
of a cysteine residue at position 115 with tryptophan. This
non-conservative amino acid substitution is also likely to inacti-
vate the resultant protein product. Our ﬁndings are consistent with
compound 14 functioning as a pro-drug in wild-type M. tuberculo-
sis. Since Rv3161c is not essential, it seems unlikely this is the
target. We propose that Rv3161c is able to modify the DAQ
compounds and that the resulting metabolite is the active species.
Inactivation of Rv3161c would thus lead to resistance.
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Based on previous reports of sub-micromolar MIC activity of the
DAQ series in TB assays, the main goal of our work was to deter-
mine whether the series is a viable starting point for drug lead
development. Surprisingly, we found the activity of the series in
liquid medium was limited and anti-tubercular activity was
weaker than previously reported. We hypothesized that this dis-
parity was a result of variation in assay conditions, the most
noticeable difference being a change in carbon source. However,
we saw no improvement in anti-tubercular activity of these com-
pounds when tested using palmitate as a carbon source. In previ-
ous work, cell viability was determined by metabolic activity
(using Alamar blue), whereas we measured bacterial growth (by
OD and ﬂuorescence). This may be indicative of mode of action,
since compounds might be able to reduce metabolic activity more
efﬁciently than prevent growth.
However, good activity was seen on solid medium for these
compounds where the MICs were lower than in liquid medium
(even using the same carbon source, glucose). This was surprising,
since in our experience MICs on solid medium are normally higher
by several-fold. This may reﬂect a true difference in bacterial phys-
iology or metabolism between the two states. Culture on solid
medium may reﬂect better the physiological state of bacteria dur-
ing infection, particularly in granulomas or in bioﬁlms.
We conducted a systematic exploration of a diaminoquinazo-
line compound series for inhibitory activity against M. tuberculosis.
SAR efforts around N-3 replacements led to a fused ring in the form
of an imidazoquinoline (103) with an improvement in biological
activity and an opportunity for SAR development on an alternate
scaffold. PK evaluation indicated there is no obvious barrier to
property optimization. Our data demonstrated that the DAQ series
had an encouraging microbiological proﬁle with bactericidal activ-
ity against replicating and non-replicatingM. tuberculosis, suggest-
ing that the target of the series is important for bacterial viability.
Future work to identify the target could allow screening for alter-
native scaffolds with improved properties and biological activity.
These properties may have implications in the application of these
compounds as anti-TB agents. In addition, the DAQ series could be
useful tools for probing cell death mechanisms and for target iden-
tiﬁcation studies.
4. Experimental section
4.1. Determination of minimum inhibitory concentration (MIC)
M. tuberculosis H37Rv was grown in Middlebrook 7H9 medium
containing 10% OADC (oleic acid, albumin, dextrose, catalase)
supplement (Becton Dickinson) and 0.05% w/v Tween 80 (7H9-
Tw-OADC). Liquid MICs were performed in 96-well plates as
described.14 Brieﬂy, compounds were solubilized in DMSO and
assayed using a 10-point two-fold serial dilution with the highest
concentration of 20 lM. Bacterial growth was measured by OD
after 5 days of incubation at 37 C; growth curves were ﬁtted to
the Gompertz model. The MIC was deﬁned as the minimum con-
centration required for complete growth inhibition. In order to
generate an MIC, two points of complete inhibition were required;
where MICs could not be calculated the % inhibition of growth at
20 lM was recorded. Inhibition of >30% was recorded as active,
<30% was recorded as inactive. Data are from one run. The assay
was validated according to NCGC guidelines with reproducibility
between runs of <2-fold for MIC values.14 MIC99 was determined
on solid medium (Middlebrook 7H10 plus 10% v/v OADC) using
the serial proportion method15: MIC was deﬁned as the minimum
concentration required to prevent 99% of growth.4.2. Kill kinetics
For aerobic kill curves, cells were inoculated to a theoretical
OD590 of 0.01 (theoretical) in 10 mL medium containing Compound
14. For the starvation-kill determinations, 10 mL of culture was
grown to mid-log phase, harvested by centrifugation for 10 min
at 4000 rpm, and re-suspended in phosphate buffered saline. Cells
were maintained as standing cultures at 37 C for 2 weeks prior to
the addition of compound to ensure that cells had adapted to the
non-replicating state. Colony forming units were enumerated by
plating dilutions of cells onto compound free plates at the indi-
cated time points.4.3. Growth curves
Growth curves were carried out in 16 mm diameter glass tubes
with 2 mm stirrer bars containing 5 mL of 7H9-Tw-OADC medium
plus 40 lg/mL hemin where required; 2 tubes were inoculated to a
theoretical OD590 of 0.04. Cultures were incubated at 37 C with
stirring. For studies using palmitate as a carbon source, OADC
and Tween 80 were omitted and medium was supplemented with
5 g/L BSA fraction V, 0.8 g/L NaCl, 0.05% v/v Tyloxapol and 0.25 mM
palmitic acid.
4.4. Pharmacokinetics
Male Sprague-Dawley rats (250–350 g) were purchased from
Harlan (Indianapolis, IN). The Institutional Animal Care and Use
Committees at Covance and Harlan approved all animal proce-
dures. Three rats were dosed per treatment group. Plasma samples
were collected over 24 h in an intravenous/oral crossover study
with a 1 day washout period between drug administrations. On
day 0, compound was administered by intravenous bolus injection
(1 mg/kg; 2 ml/kg, Captisol 20% w/v/NaPO4 buffer 25 mM, pH2, q.s)
and on day 1 by oral gavage (10 mg/kg; 10 mL/kg HEC 1% w/v/P80
0.25% v/v/AF 1510-US 0.05% v/v/DIW, q.s.). Arterial blood samples
were collected at the following times after dose administration:
0 (oral arm only), 0.08 (intravenous arm only), 0.25, 0.5, 1, 2, 4,
8, 12, and 24 h.
Compound concentrations in plasma were quantiﬁed by LC-MS/
MS. All samples were mixed with an organic internal standard
solution to precipitate protein and centrifuged. The resulting
supernatants were analyzed. Analytes were separated using a Beta-
sil C18 (2.1  20 mm, 5 lm; Thermo Fisher Scientiﬁc, Waltham,
MA) with gradient elution. All analytes were detected in positive
ion mode reaction monitoring (Sciex API 4000 triple quadrupole
mass spectrometer equipped with a TurboIonSpray interface;
Applied Biosystems/MDS, Foster City, CA): The dynamic range of
the assays was 1 to either 1250 or 5000 ng/mL for all analytes.
Samples with analyte concentrations above the upper limit of
quantiﬁcation were diluted with matrix to within the assay range;
concentrations below the lower limit of quantiﬁcation (BQL) were
reported as BQL. All bioanalytical assays met acceptance criteria for
accuracy (<±30% relative error) and precision (<30% relative SD).
Noncompartmental pharmacokinetic parameters were calculated
using Watson (version 7.4; Thermo Fisher Scientiﬁc).4.5. Resistant mutant isolation and characterization
Resistant mutants were isolated by plating 107, 108, or 109
bacteria onto agar plates containing 5X and 10X the solid MIC of
compound. Resistant colonies were streaked onto plates contain-
ing compound and MICs were determined on solid medium to con-
ﬁrm resistance. Genomic DNA was prepared16 and whole genome
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4.6. Compound synthesis
4.6.1. General methods
1H and 13C NMR spectral data were recorded in CDCl3 or
DMSO-d6 on a 300 or 400 MHz Bruker NMR spectrometer. Column
chromatography was conducted on silica gel (100–300 mesh).
Reactions were monitored using thin-layer chromatography (TLC)
on silica gel plates. HPLC analysis was conducted on an Agilent
1100 series LC system (Agilent ChemStation Rev.A.10.02; Phenom-
enex-Luna-C18, 4.8 mm  150 mm, 5 lm, 1.0 mL/min, UV 254 nm,
room temperature) with MeCN/H2O (0.05% TFA or HCOOH buffer)
gradient elution. HPLC-MS was performed on a Gilson 321 HPLC
with detection performed by a Gilson 170 DAD and a Finnigan
AQA mass spectrometer operating in electrospray ionisation mode
using a Phenomenex Gemini C18 150  4.6 mm column. Purity
was determined using a Waters Acquity UPLC system equipped
with a BEH C18 1.7 lm 2.1  100 mm column.
4.6.1.1. Representative procedure I for preparation of 2,4-
diaminoquinazolines 4–31, 36–53 and amino ethers 22,
23. To a stirred solution of substituted 2,4-dichloroquinazoline9
(1 equiv) in THF were added an amine (1 equiv) and triethylamine
(2 equiv). The reaction was allowed to stir at room temperature for
10–12 h and progress followed by TLC. The reaction mixture was
quenched with addition of ice-water (40 mL) and extracted with
CH2Cl2 (60 mL/g). The organic layer was dried over anhydrous
Na2SO4, ﬁltered and concentrated under reduced pressure. Crude
products were puriﬁed by column chromatography on silica gel
(100–200 mesh) to afford pure 2-chloro-4-aminoquinazoline
intermediates.
To a stirred solution of 2-chloro-4-aminoquinazoline intermedi-
ate (1 equiv) in isopropyl alcohol was added an amine (2 equiv).
The reaction mixture was heated in a sealed vial at 120 C for
3–6 h and reaction monitored by TLC. The reaction mixture was
quenched with addition of ice-water (40 mL) then extracted with
ethyl acetate (60 mL/g). The organic layer was dried over anhy-
drous Na2SO4, ﬁltered and concentrated under reduced pressure.
Crude products were puriﬁed by column chromatography on silica
gel (100–200 mesh) to afford pure products.
4.6.1.2. N-Benzyl-2-(piperidin-1-yl)quinazolin-4-amine (4).N-
Benzyl-2-(piperidin-1-yl)quinazolin-4-amine (4) was purchased
from Princeton Biomolecular.
4.6.1.3. N-(2-Fluorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
(5).N-(2-Fluorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine (5)
was prepared according to the representative procedure I. MS: ESI-
MS, m/z: 337.2 (M+1). 1H NMR (300 MHz, DMSO-d6): d 1.36–1.44
(4H, m), 1.53–1.61 (2H, m), 3.68–3.72 (4H, m), 4.71 (2H, d,
J = 5.7 Hz), 7.05 (1H, ddd, J = 8.9 Hz, 6.9 Hz and 1.2 Hz), 7.09–7.31
(3H, m), 7.39 (1H, td, J = 7.7 Hz and 1.8 Hz), 7.49 (1H, ddd,
J = 8.5 Hz, 6.9 Hz and 1.5 Hz), 8.02 (1H, dd, J = 8.2 Hz and 1.1 Hz),
8.50 (1H, t, J = 5.6 Hz).
4.6.1.4. N-(3-Fluorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
(6).N-(3-Fluorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine (6) was
prepared according to the representative procedure I. MS: ESI-MS,m/
z: 337.2 (M+1). 1H NMR (300MHz, DMSO-d6): d 1.37–1.44 (4H, m),
1.53–1.61 (2H, m), 3.69–3.72 (4H, m), 4.67 (2H, d, J = 5.67 Hz), 7.08–
7.00 (2H, m), 7.15–7.26 (3H, m), 7.31–7.38 (1H, m), 7.49 (1H, ddd,
J = 8.4 Hz, 6.9 Hz and 1.4 Hz), 8.00 (1H, dd, J = 8.2 Hz and 1.0 Hz),
8.55 (1H, t, J = 5.9 Hz).4.6.1.5. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
(7).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine (7) was
prepared according to the representative procedure I. MS: ESI-MS,
m/z: 337 (M+1); HRMS (ESMS) calcd for C20H21FN4, 337.1823; found,
337.1824 (M+1). 1H NMR (300MHz, DMSO-d6): d 1.45–1.70 (6H, m),
3.80 (4H, br s), 4.76 (2H , d, J = 5.6 Hz), 7.17 (2H, dt, J = 8.8 Hz,
1.2 Hz), 7.42–7.48 (3H, m), 7.68 (1H, d, J = 8.4 Hz), 7.81 (1H, t,
J = 7.8 Hz), 8.27 (1H, d, J = 8.2 Hz).
4.6.1.6. N-(3-Methylbenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
hydrochloride (8).N-(3-Methylbenzyl)-2-(piperidin-1-yl)quinazolin-
4-amine hydrochloride (8) was prepared according to the representa-
tive procedure I. MS: ESI-MS, m/z: 333.3 (M+1). 1H NMR (300MHz,
DMSO-d6): d 1.50–1.71 (6H, br m), 2.28 (3H, s), 3.78–3.87 (4H, br m),
4.73 (2H, d, J = 5.8 Hz), 7.05–7.11 (1H, d, J = 6.5 Hz), 7.16–7.26 (3H, br
m), 7.44 (1H, td, J = 7.6 Hz and 1.5 Hz), 7.71–7.85 (2H, br m), 8.31
(1H d, J = 8.3 Hz).
4.6.1.7. N-(3-Iodobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
(9).N-(3-Iodobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine (9)
was prepared according to the representative procedure I. MS:
ESI-MS, m/z: 445.1 (M+1); HRMS (ESMS) calcd for C20H21IN4,
445.0884; found, 445.0882 (M+1). 1H NMR (300 MHz, CDCl3): d
1.61–1.80 (6H, br m), 3.85–3.89 (4H, br m), 4.75 (2H, d,
J = 5.7 Hz), 5.81–5.92 (1H, br s), 7.09 (2H, q, J = 7.8 Hz), 7.37 (1H,
d, J = 7.2 Hz), 7.42–7.58 (3H, m), 7.63 (1H, d, J = 6.9 Hz), 7.79 (1H, s).
4.6.1.8. N-(4-Methylbenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
(10).N-(4-Methylbenzyl)-2-(piperidin-1-yl)quinazolin-4-amine (10)
was prepared according to the representative procedure I. MS: ESI-
MS, m/z: 333.2 (M+1). 1H NMR (300MHz, DMSO-d6): d 1.39–1.49
(4H, m), 1.53–1.63 (2H, m), 2.25 (3H, s), 3.73 (4H, t, J = 5.3 Hz), 4.62
(2H, d, J = 5.8 Hz), 7.02 (1H, ddd, J = 8.1 Hz, 7.0 Hz and 1.2 Hz), 7.10
(2H, d, J = 7.8 Hz), 7.23 (1H, d, J = 7.9 Hz), 7.26 (2H, d, J = 8.1 Hz), 7.47
(1H, ddd, J = 8.2 Hz, 6.8 Hz and 1.3 Hz), 7.99 (1H, dd, J = 8.3 Hz and
1.1 Hz), 8.47 (1H, t, J = 6.3 Hz).
4.6.1.9. N-(4-Methoxybenzyl)-2-(piperidin-1-yl)quinazolin-4-
amine (11).N-(4-Methoxybenzyl)-2-(piperidin-1-yl)quinazolin-
4-amine (11) was prepared according to the representative
procedure I. MS: ESI-MS, m/z: 349.2 (M+1). 1H NMR (300 MHz,
DMSO-d6): d 1.40–1.50 (4H, m), 1.55–1.64 (2H, m), 3.70 (3H, s),
3.75 (4H, t, J = 5.3 Hz), 4.61 (2H, d, J = 5.9 Hz), 6.86 (2H, d,
J = 8.7 Hz), 7.02 (1H, ddd, J = 8.1 Hz, 7.1 Hz and 1.1 Hz), 7.23
(1H, dd, J = 8.4 Hz and 0.8 Hz), 7.30 (2H, d, J = 8.7 Hz), 7.47 (1H,
ddd, J = 8.3 Hz, 7.0 Hz and 1.2 Hz), 7.98 (1H, dd, J = 8.2 Hz and
1.1 Hz), 8.47 (1H, t, J = 5.8 Hz).
4.6.1.10. 2-(Piperidin-1-yl)-N-(4-(triﬂuoromethoxy)benzyl)qui-
nazolin-4-amine (12).2-(Piperidin-1-yl)-N-(4-(triﬂuoromethoxy)
benzyl)quinazolin-4-amine (12) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 403.1(M+1). 1H
NMR (300 MHz, DMSO-d6): d 1.33–1.43 (4H, br m), 1.51–1.61
(2H, br s), 3.65–3.72 (4H, br m), 4.68 (2H, d, J = 5.8 Hz), 7.05 (1H,
td, J = 7.6 Hz and 1.2 Hz), 7.22–7.33 (3H, br s), 7.45–7.52 (3H, br
s), 8.00 (1H, d, J = 8.2 Hz), 8.56 (1H, br s).
4.6.1.11. N-(4-Chlorobenzyl)-2-(piperidin-1-yl)quinazolin-4-ami
ne (13).N-(4-Chlorobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
(13) was prepared according to the representative procedure I. MS:
ESI-MS, m/z: 353.1 (M+1). 1H NMR (300 MHz, DMSO-d6): d 1.37–
1.44 (4H, m), 1.54–1.61 (2H, m), 3.69 (4H, t, J = 5.3 Hz), 4.64 (2H, d,
J = 5.7 Hz), 7.04 (1H, ddd, J = 8.0 Hz, 7.0 Hz and 1.0 Hz), 7.22–7.25
(1H, d, J = 7.6 Hz), 7.33–7.40 (4H, m), 7.48 (1H, ddd, J = 8.3 Hz,
7.0 Hz and 1.2 Hz), 7.98 (1H, d, J = 7.58 Hz), 8.54 (1H, t, J = 6.0 Hz).
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olin-4-amine (14).2-(Piperidin-1-yl)-N-(4-(triﬂuoromethyl)ben
zyl)quinazolin-4-amine (14) was prepared according to the repre-
sentative procedure I. MS: ESI-MS, m/z: 387 (M+1); HRMS (ESMS)
calcd for C21H21F3N4, 387.1791; found, 387.1793 (M+1). 1H NMR
(300 MHz, DMSO-d6): d 1.50–1.64 (6H, m), 3.74–3.77 (4H, m), 4.86
(2H, d, J = 5.5 Hz), 7.47 (1H, t, J = 7.6 Hz), 7.59–7.73 (5H, m), 7.83
(1H, t, J = 7.5 Hz), 8.28 (1H, d, J = 7.9 Hz).4.6.1.13. N-(4-Aminobenzyl)-2-(piperidin-1-yl)quinazolin-4-ami
ne (15).N-(4-Aminobenzyl)-2-(piperidin-1-yl)quinazolin-4-amine
(15) was prepared from a nitro derivative according to the represen-
tative procedure I. The nitro groupwas further reduced to the desired
aniline product. HRMS (ESMS) calcd for C20H23N5, 334.2026; found,
334.2030 (M+1). 1H NMR (300 MHz, CDCl3): d 1.59–1.67 (6H, m),
3.79–3.83 (4H, m), 4.68 (2H, d, J = 5.4 Hz), 6.83 (2H, d, J = 7.8 Hz),
7.23 (2H, d, J = 8.4 Hz), 7.45 (1H, t, J = 8.1 Hz), 7.67 (1H, d, J = 8.1 Hz)
7.80 (1H, t, J = 7.2 Hz) 8.26 (1H, d, J = 8.4 Hz), 9.95 (1H, m).
4.6.1.14. N-(2,4-Diﬂuorobenzyl)-2-(piperidin-1-yl)quinazolin-4-
amine hydrochloride (16).N-(2,4-Diﬂuorobenzyl)-2-(piperidin-1-
yl)quinazolin-4-amine hydrochloride (16) was prepared according
to the representative procedure I. MS: ESI-MS,m/z: 355.3(M+1). 1H
NMR (300 MHz, DMSO-d6): d 1.49–1.71 (6H, br m), 3.77–3.88 (4H,
m), 4.77 (2H, d, J = 5.5 Hz), 7.02–7.12 (1H, td, J = 8.5 Hz and 2.5 Hz),
7.22–7.32 (1H, m), 7.40–7.58 (2H, m), 7.77–7.87 (2H, m), 8.36 (1H,
d, J = 8.3 Hz), 10.09–10.17 (1H, br m), 11.97 (1H, br s).
4.6.1.15. N-(3,4-Diﬂuorobenzyl)-2-(piperidin-1-yl)quinazolin-4-
amine hydrochloride (17).N-(3,4-Diﬂuorobenzyl)-2-(piperidin-1-
yl)quinazolin-4-amine hydrochloride (17) was prepared according
to the representative procedure I. MS: ESI-MS,m/z: 355.2 (M+1). 1H
NMR (300 MHz, DMSO-d6): d 1.49–1.70 (6H, br m), 3.76–3.87 (4H,
m), 4.75 (2H, d, J = 5.5 Hz), 7.22–7.30 (1H, m), 7.34–7.56 (3H, m),
7.76–7.85 (2H, m), 8.33 (1H, d, J = 8.1 Hz), 10.16 (1H, s), 11.80
(1H, br s).
4.6.1.16. N-(2,4-Dichlorobenzyl)-2-(piperidin-1-yl)quinazolin-4-
amine (18).N-(2,4-Dichlorobenzyl)-2-(piperidin-1-yl)quinazolin-
4-amine (18) was prepared according to the representative
procedure I. MS: ESI-MS, m/z: not found. 1H NMR (300 MHz,
DMSO-d6): d 1.30–1.42 (4H, br m), 1.49–1.60 (2H, br m), 3.59–
3.69 (4H, br m), 4.71 (2H, d, J = 5.7), 7.07 (1H, td, J = 7.5 Hz and
1.2 Hz), 7.26 (1H, dd, J = 8.5 Hz and 0.8 Hz), 7.35 (2H, d, J = 1.2 Hz),
7.50 (1H, td, J = 7.7 Hz and 1.4 Hz), 7.61 (1H, t, J = 1.1 Hz), 8.03
(1H, dd, J = 8.3 Hz and 1.1 Hz), 8.57 (1H, t, J = 5.6 Hz).
4.6.1.17. N-(3,4-Dichlorobenzyl)-2-(piperidin-1-yl)quinazolin-4-
amine (19).N-(3,4-Dichlorobenzyl)-2-(piperidin-1-yl)quinazolin-
4-amine (19) was prepared according to the representative
procedure I. MS: ESI-MS, m/z: 387.1(M+1). 1H NMR (300 MHz,
DMSO-d6): d 1.45–1.34 (4H, br m), 1.52–1.62 (2H, br m), 3.64–
3.73 (4H, br m), 4.63 (2H, d, J = 5.9), 7.05 (1H, td, J = 7.6 Hz and
1.1 Hz), 7.24 (1H, dd, J = 8.5 Hz and 0.9 Hz), 7.34 (1H, dd,
J = 8.5 Hz and 2.0 Hz), 7.49 (1H, td, J = 7.6 Hz and 1.4 Hz), 7.56
(1H, d, J = 8.2 Hz), 7.62 (1H, d, J = 2.0 Hz), 7.97 (1H, dd, J = 8.2 Hz
and 1.1 Hz), 8.57 (1H, t, J = 5.8 Hz).
4.6.1.18. N-(2,4-Dichlorobenzyl)-2-(piperidin-1-yl)quinazolin-4-
amine (20).N-(2,4-Dichlorobenzyl)-2-(piperidin-1-yl)quinazolin-
4-amine (20) was prepared according to the representative
procedure I. MS: ESI-MS, m/z: not found. 1H NMR (300 MHz,
DMSO-d6): d 1.30–1.42 (4H, br m), 1.49–1.60 (2H, br m), 3.59–
3.69 (4H, br m), 4.71 (2H, d, J = 5.7 Hz), 7.07 (1H, td, J = 7.5 Hz and
1.2 Hz), 7.26 (1H, dd, J = 8.5 Hz and 0.8 Hz), 7.35 (2H, d, J = 1.2 Hz),7.50 (1H, td, J = 7.7 Hz and 1.4 Hz), 7.61 (1H, t, J = 1.1 Hz), 8.03
(1H, dd, J = 8.3 Hz and 1.1 Hz), 8.57 (1H, t, J = 5.6 Hz).
4.6.1.19. N-(3-Chloro-4-methoxybenzyl)-2-(piperidin-1-yl)qui-
nazolin-4-amine (21).N-(3-Chloro-4-methoxybenzyl)-2-(piperi-
din-1-yl)quinazolin-4-amine (21) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 383.2 (M+1); HRMS
(ESMS) calcd for C21H23ClN4O, 383.1633; found, 383.1635 (M+1).
LCMS: 99.3% purity. 1H NMR: (300 MHz, CDCl3): d 1.40–1.50 (4
H, m), 1.55–1.64 (2 H, m), 3.75 (4 H, m), 3.80 (3 H, s), 4.60 (2 H,
m), 7.02–7.11 (2 H, m), 7.23–7.31 (2 H, m), 7.40–7.51 (2 H, m),
7.91 (1H, d, J = 8.2 Hz), 8.10 (1H, s), 8.5–8.6 (1H, m).
4.6.1.20. 4-(4-Fluorobenzyloxy)-2-(piperidin-1-yl)quinazoline
(22).4-(4-Fluorobenzyloxy)-2-(piperidin-1-yl)quinazoline (22)
was prepared according to the representative procedure I substi-
tuting (4-ﬂuorophenyl)methanol for the amine in the initial
reaction step. Yield: 118 mg, 44%. MS: ESI-MS, m/z: 338.19
(M+1); HRMS (ESMS) calcd for C20H20FN3O, 338.1663; found,
338.1664 (M+1). LCMS: 99% purity. 1H NMR: (400 MHz, CDCl3): d
1.61–1.69 (6H, m), 3.86–3.90 (4H, m), 5.50 (2H, s), 7.03–7.13 (3H,
m), 7.44–7.50 (3H, m), 7.58 (1H, t, J = 5.6 Hz), 7.91 (1H, d,
J = 7.2 Hz).
4.6.1.21. 4-(4-Fluorobenzylthio)-2-(piperidin-1-yl)quinazoline
(23).4-(4-Fluorobenzylthio)-2-(piperidin-1-yl)quinazoline (23)
was prepared according to the representative procedure I
substituting (4-ﬂuorophenyl)methanethiol for the amine in the ini-
tial reaction step. Yield 54 mg, 35%. MS: ESI-MS, m/z: 354.19
(M+1); HRMS (ESMS) calcd for C20H20FN3S, 354.1435; found,
354.1437 (M+1). LCMS: 93.9% purity. 1H NMR: (400 MHz, CDCl3):
d 1.60–1.75 (6H, m), 3.89–3.94 (4H, m), 4.51 (2H, s), 6.97–7.02
(2H, m), 7.05–7.12 (1H, m), 7.38–7.42 (2H, m), 7.45–7.50 (1H,
m), 7.54–7.60 (1H, m), 7.77 (1H, dd, J = 7.6 Hz).
4.6.1.22. N-Methyl-2-(piperidin-1-yl)quinazolin-4-amine (24).N-
Methyl-2-(piperidin-1-yl)quinazolin-4-amine (24) was prepared
according to the representative procedure I. MS: ESI-MS, m/z:
243.16 (M+1); HRMS (ESMS) calcd for C14H18N4, 243.1604; found,
243.1605 (M+1), LCMS: 99.4% purity. 1H NMR: (400MHz, CDCl3):
d 1.60–1.65 (6H, m), 3.14 (3H, d, J = 4.4 Hz) 3.85–3.92 (4H, m),
5.44–5.50 (1H, m), 6.99–7.05 (1H, m), 7.41–7.50 (3H, m).
4.6.1.23. N-Isobutyl-2-(piperidin-1-yl)quinazolin-4-amine (25).N-
Isobutyl-2-(piperidin-1-yl)quinazolin-4-amine (25) was prepared
according to the representative procedure I. MS: ESI-MS, m/z: 285
(M+1); HRMS (ESMS) calcd for C17H24N4, 285.2074; found,
285.2077 (M+1). 1H NMR (300MHz, DMSO-d6): d 1.67 (4H, br s),
2.06 (1H, septet, J = 6.7 Hz), 3.84 (4H, br s), 7.43 (1H, t, J = 7.6 Hz),
7.67 (1H, d, J = 8.0 Hz), 7.78 (1H, t, J = 7.4 Hz), 8.27 (1H d,
J = 7.9 Hz), 9.48 (1H t, J = 5.2 Hz), 11.7 (1H, s).
4.6.1.24. N-(Cyclohexylmethyl)-2-(piperidin-1-yl)quinazolin-4-
amine (26).N-(Cyclohexylmethyl)-2-(piperidin-1-yl)quinazolin-4-
amine (26) was prepared according to the representative
procedure I. MS: ESI-MS, m/z: 325.3 (M+1). 1H NMR (300 MHz,
DMSO-d6): d 0.89–1.04 (2 H, m), 1.10–1.24 (3 H, m), 1.44–1.54 (4
H, m), 1.56–1.79 (8 H, m), 3.70 (3 H, s), 3.77 (4 H, t, J = 5.4), 7.00
(1H, ddd, J = 8.1, 6.9 and 1.2), 7.22 (1H, dd, J = 8.4 and 0.9), 7.45
(1H, ddd, J = 8.3, 6.9 and 1.4), 7.89 (1H, t, J = 5.6), 7.97 (1H, dd,
J = 8.1 and 0.8).
4.6.1.25. 2-(Piperidin-1-yl)-N-(4-(triﬂuoromethyl)phenethyl)qui
nazolin-4-amine (27).2-(Piperidin-1-yl)-N-(4-(triﬂuoromethyl)
phenethyl)quinazolin-4-amine (27) was prepared according to
the representative procedure I. MS: ESI-MS, m/z: 401.3 (M+1). 1H
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br m), 8.19 (1H, d, J = 8.3), 9.55 (1H, br s), 11.70 (1H, br s).
4.6.1.26. N-(Naphthalen-1-ylmethyl)-2-(piperidin-1-yl)quinazo-
lin-4-amine (28).N-(Naphthalen-1-ylmethyl)-2-(piperidin-1-
yl)quinazolin-4-amine (28) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: MH+ 369.3(M+1). 1H
NMR (300 MHz, DMSO-d6): d 1.34–1.44 (4 H, m), 1.51–1.60 (2 H,
m), 3.69 (4 H, t, J = 5.4), 5.16 (2 H, d, J = 5.4), 7.02 (1H, ddd,
J = 8.1, 7.0 and 1.1), 7.24 (1H, dd, J = 8.4 and 0.8), 7.43–7.58 (5 H,
m), 7.83 (1H, d, J = 8.1), 7.91–7.96 (1H, m), 8.05 (1H, d, J = 7.3),
8.30 (1H, dd, J = 7.1 and 2.2), 8.30 (1H, dd, J = 7.1 and 2.2), 8.49
(1H, t, J = 5.2).
4.6.1.27. N-(4-Fluorophenyl)-2-(piperidin-1-yl)quinazolin-4-
amine (29).N-(4-Fluorophenyl)-2-(piperidin-1-yl)quinazolin-4-
amine (29) was prepared according to the representative
procedure I. Yield: 100 mg, 27%. MS: ESI-MS, m/z: 323.14 (M+1);
HRMS (ESMS) calcd for C19H19FN4, 323.1667; found, 323.1669
(M+1). UPLC: 98.5% purity. 1H NMR: (400 MHz, DMSO-d6): d
1.46–1.53 (4H, m), 1.58–1.64 (2H, m), 3.70–3.77 (4H, m), 7.14 (1H, t,
J = 7.6 Hz), 7.22 (2H, t, J = 8.8 Hz), 7.33 (1H, d, 8.4 Hz), 7.56 (1H, t ,
J = 7.2 Hz), 7.75–7.82 (2H, m), 8.24 (1H, d, J = 8 Hz), 9.52 (1H, s).
4.6.1.28. 2,4-Di(piperidin-1-yl)quinazoline (30).2,4-Di(piperidin-
1-yl)quinazoline (30) was prepared according to the representative
procedure I. MS: ESI-MS, m/z: 297.2 (M+1). 1H NMR (300 MHz,
DMSO-d6): d 1.72 – 1.45 (m, 12H), 3.57–3.51 (m, 4H), 3.78 (br t,
J = 5.2 Hz, 4H), 7.06 (t, J = 7.2 Hz, 1H), 7.43 (d, J = 8.2 Hz, 1H), 7.50
(t, J = 7.5 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H).
4.6.1.29. 4-(6-Fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2-(piper-
idin-1-yl)quinazoline (31).4-(6-Fluoro-3,4-dihydroisoquinolin-
2(1H)-yl)-2-(piperidin-1-yl)quinazoline (31) was prepared
according to the representative procedure I. Yield: 42 mg, 45%.
MS: ESI-MS, m/z: 363.13 (M+1); HRMS (ESMS) calcd for
C22H23FN4, 363.1980; found, 363.1980 (M+1). UPLC: 97.7% purity.
1H NMR: (400 MHz, DMSO-d6): d 1.47–1.55 (4H, m), 1.58–1.63
(2H, m), 3.08 (2H, t, J = 5.6 Hz), 3.77–3.82 (4H, m), 3.87 (2H, t,
J = 5.6 Hz), 4.77 (2H, s), 7.02 (1H, t, J = 8.4 Hz), 7.04–7.12 (2H, m),
7.29 (1H, t, J = 6 Hz), 7.36 (1H, d, J = 8.4 Hz), 7.54 (1H, t,
J = 7.6 Hz), 7.82 (1H, d, J = 8 Hz).
4.6.1.30. 2-(Piperidin-1-yl)quinazoline (34).A solution of quinaz-
olin-2(1H)-one (1 g, 6.7 mmol) in POCl3 (15 mL) was heated in a
sealed tube at 100 C overnight. The reaction progress was fol-
lowed by TLC. Reaction mixture was concentrated under reduced
pressure and co-distilled with toluene. The resulting residue was
dissolved in ethyl acetate (60 mL) and washed with aqueous
NaHCO3 (30 mL) and brine solution (30 mL). The organic layer
was dried over Na2SO4, ﬁltered and concentrated under reduced
pressure. Crude product was then puriﬁed by column chromatog-
raphy on (100–200 mesh) silica gel using ethyl acetate in hexane
to give 2-chloroquinazoline (0.79 g, 71.8%).
To a stirred solution of 2-chloroquinazoline (70 mg, 0.43 mmol)
in MeCN was added piperidine (181 mg, 2.1 mmol) and K2CO3
(312 mg, 2.26 mmol) then heated in a sealed tube at 90 C over-
night. The reaction was monitored by TLC. The reaction was
quenched with addition of ice-water (30 mL), concentrated to
remove the MeCN then extracted with CH2Cl2 (2  30 mL). The
organic extract was dried over Na2SO4, ﬁltered and concentrated
under reduced pressure. Crude product was puriﬁed by column
chromatography on (100–200 mesh) silica gel using ethyl acetate
in hexane to afford 2-(piperidin-1-yl)quinazoline (85 mg, 94%).
MS: ESI-MS, m/z: 214.46 (M+1), LCMS: 99.4% purity. 1H NMR:(400 MHz, CDCl3): d 1.74–1.87 (6H, m), 3.69–3.77 (4H, m), 7.43
(1H, t, J = 7.6 Hz), 7.71 (1H, t, J = 8 Hz), 7.86 (2H, d, J = 8.8 Hz),
8.71 (1H, s).
4.6.1.31. 4-(4-Fluorophenethyl)-2-(piperidin-1-yl)quinazoline
(35).4-(4-Fluorophenethyl)-2-(piperidin-1-yl)quinazoline (35)
was similarly prepared from 4-(4-ﬂuorophenethyl)quinazolin-
2(3H)-one9,10 following the procedure described for synthesis of
34. MS: ESI-MS, m/z: 336.31 (M+1), LCMS: 95.8% purity. 1H NMR:
(400 MHz, DMSO-d6): d 1.51–1.57 (4H, m), 1.61–1.69 (2H, m),
3.13 (2H, t, J = 8 Hz), 3.44 (2H, t, J = 8 Hz), 3.82–3.90 (4H, m), 7.08
(2H, t, J = 8.8 Hz), 7.18(1H, t, J = 7.2 Hz), 7.31–7.35 (2H, m), 7.44
(1H, d, J = 8.4 Hz), 7.64 (1H, t, J = 6.8 Hz), 7.99 (1H, d, J = 8 Hz).
4.6.1.32. N-(4-Fluorobenzyl)-2-(4-methylpiperidin-1-yl)quinaz-
olin-4-amine (36).N-(4-Fluorobenzyl)-2-(4-methylpiperidin-1-yl)
quinazolin-4-amine (36) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 351.23 (M+1); HRMS
(ESMS) calcd for C21H23FN4, 351.1980; found, 351.1981 (M+1).
LCMS: 99.3% purity. 1H NMR: (400 MHz, DMSO-d6): d 0.88 (3H, d,
J = 6 Hz),0.94 (2H, t, J = 9.2 Hz), 1.52–1.60 (3H, m), 2.73 (2H, t,
J = 11.2 Hz), 4.64 (2H, d, J = 6 Hz), 4.67–4.71 (2H, m), 7.03 (1H,
dd, J = 8 Hz), 7.09–7.14 (2H, m), 7.23 (1H, d, J = 8.4 Hz), 7.38–7.41
(2H, m), 7.48 (1H, dd, J = 5.6 Hz), 7.98 (1H, d, J = 7.2 Hz), 8.51 (1H,
t, J = 6 Hz, NH).
4.6.1.33. 1-(4-(4-Fluorobenzylamino)quinazolin-2-yl)piperidin-
4-ol (37).1-(4-(4-Fluorobenzylamino)quinazolin-2-yl)piperidin-4-
ol (37) was prepared according to the representative procedure I.
MS: ESI-MS, m/z: 353.21 (M+1); HRMS (ESMS) calcd for
C20H21FN4O, 353.1772; found, 353.1777 (M+1). LCMS: 99.4%
purity. 1H NMR: (400MHz, DMSO-d6): d 1.19–1.24 (2H, m), 1.67–1.70
(2H, t), 3.12 (2H, t, J = 10 Hz), 3.62–3.66 (1H, m), 4.31–4.34 (2H,
m), 4.61–4.65 (3H, m), 7.04 (1H, t, J = 7.6 Hz), 7.12 (2H, t, J =
8.8 Hz), 7.24 (1H, d, J = 8.4 Hz), 7.38–7.41 (2H, m), 7.48 (1H, t,
J = 7.2 Hz), 7.99 (1H, d, J = 8 Hz), 8.54 (1H, t, NH).
4.6.1.34. 2-(4-Aminopiperidin-1-yl)-N-(4-ﬂuorobenzyl)quinazo-
lin-4-amine (38).2-(4-Aminopiperidin-1-yl)-N-(4-ﬂuorobenzyl)
quinazolin-4-amine (38) was prepared according to the represen-
tative procedure I. MS: ESI-MS, m/z: 352.29 (M+1), LCMS: 98.2%
purity. 1H NMR: (400 MHz, DMSO-d6): d 1.02–1.15 (2H, m), 1.65–
1.71 (2H, m), 2.70–2.75 (1H, m), 2.84–2.93 (2H, m), 4.54–4.57
(2H, m), 4.64 (2H, d, J = 5.6 Hz), 7.03 (1H, t, J = 7.6 Hz), 7.11(2H, t,
J = 8.8 Hz), 7.23 (1H, d, J = 8 Hz), 7.38–7.42 (2H, m), 7.47 (1H, t,
J = 7.6 Hz), 7.99 (1H, d, J = 8 Hz), 8.54(1H, t, J = 6 Hz).
4.6.1.35. N-(4-Fluorobenzyl)-2-(4-(methylamino)piperidin-1-yl)
quinazolin-4-amine (39).N-(4-Fluorobenzyl)-2-(4-(methylamino)
piperidin-1-yl)quinazolin-4-amine (39) was prepared according to
the representative procedure I. MS: ESI-MS, m/z: 366.35 (M+1),
LCMS: 96.6% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.00–1.08
(2H, m) 1.61–1.65 (1H, m), 1.74–1.77 (2H, m), 2.26 (3H, s), 2.92
(2H, t, J = 10.8 Hz), 4.51–4.54 (2H, m), 4.63 (2H, d, J = 5.6 Hz),
7.04 (1H, t, J = 8 Hz), 7.12 (2H, t, J = 8.8 Hz), 7.24 (1H, d,
J = 8.4 Hz), 7.38–7.42 (2H, m), 7.48(1H, t, J = 6.8 Hz), 7.99 (1H, d,
J = 8 Hz), 8.52 (1H, t, J = 6 Hz).
4.6.1.36. 2-(4-(Dimethylamino)piperidin-1-yl)-N-(4-ﬂuoroben-
zyl)quinazolin-4-amine (40).2-(4-(Dimethylamino)piperidin-1-
yl)-N-(4-ﬂuorobenzyl)quinazolin-4-amine (40) was prepared
according to the representative procedure I. MS: ESI-MS, m/z:
380.23 (M+1), LCMS: 97.2% purity. 1H NMR: (400 MHz, DMSO-
d6): d 1.10–1.18 (2H, m), 1.71 (2H, d, J = 11.2 Hz), 2.14 (6H, s),
2.30–2.32 (1H, m), 2.75 (2H, t, J = 8 Hz), 4.65 (2H, d, J = 5.6 Hz),
4.69–4.72 (2H, m), 7.05 (1H, t, J = 7.2 Hz), 7.12 (2H, t, J = 8.8 Hz),
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8.00 (1H, d, J = 8.4 Hz), 8.55 (1H, t, J = 5.6 Hz).
4.6.1.37. 1-(4-(4-Fluorobenzylamino)quinazolin-2-yl)piperi-
dine-4-carboxylic acid (41).1-(4-(4-Fluorobenzylamino)quinazo-
lin-2-yl)piperidine-4-carboxylic acid (41) was prepared according
to the representative procedure I. MS: ESI-MS, m/z: 381.21
(M+1), LCMS: 98% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.35–
1.43 (2H, m), 1.79–1.81 (2H, t), 2.42–2.46 (1H, m), 2.98 (2H,
t, J = 11.2 Hz), 4.52–4.55 (2H, m), 4.65 (2H, d, J = 5.2 Hz), 7.12(3H,
t, J = 8.8 Hz), 7.31 (1H, d, J = 7.6 Hz), 7.39–7.42 (2H, m), 7.53
(1H, t, 7.2 Hz), 8.04 (1H, d, J = 8 Hz), 8.74 (1H, br s), 11.94 (1H, br s).
4.6.1.38. 2-(3, 5-Dimethylpiperidin-1-yl)-N-(4-ﬂuorobenzyl)qui-
nazolin-4-amine (42).2-(3,5-Dimethylpiperidin-1-yl)-N-(4-ﬂuo-
robenzyl)quinazolin-4-amine (42) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 365.28 (M+1), LCMS:
93.1% purity. 1H NMR: (400 MHz, DMSO-d6): d 0.68–0.74 (1H, m),
0.84 (6H, d, J = 6.8 Hz), 1.33–1.48 (2H, m), 1.72 (1H, d, J = 8.4 Hz),
2.13–2.29 (2H, m), 4.63 (2H, d, J = 5.2 Hz), 4.71 (2H, d,
J = 11.6 Hz), 7.07 (1H, t, J = 7.2 Hz), 7.13–7.18 (2H, m), 7.24 (1H,
d, J = 8.4 Hz), 7.38–7.41 (2H, m), 7.49 (1H, t, J = 7.2 Hz), 7.99 (1H,
d, J = 7.6 Hz), 8.54 (1H, t, J = 5.6 Hz, NH).
4.6.1.39. (1-(4-(4-Fluorobenzylamino)quinazolin-2-yl)piperidin
-4-yl)methanol (43).(1-(4-(4-Fluorobenzylamino)quinazolin-2-
yl)piperidin-4-yl)methanol (43) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 367.26 (M+1), LCMS:
99% purity. 1H NMR: (400 MHz, DMSO-d6): d 0.93–1.01 (2H, m),
1.60–1.66 (2H, m), 2.75 (2H, t, J = 12.8 Hz), 3.23 (2H, t, J = 5.6 Hz),
4.43 (1H, t, J = 5.2 Hz), 4.65 (2H, d, J = 5.6 Hz), 4.70–4.73 (2H, m),
7.05 (1H, dd, J = 7.2 Hz), 7.12 (2H, t, 8.8 Hz), 7.26 (1H, d, J = 8 Hz)
7.38–7.42 (2H, m), 7.49 (1H, dd, J = 7.6 Hz), 8.00 (1H, d, J = 8 Hz),
8.58 (1H, br s).
4.6.1.40. 2-(1-(4-(4-Fluorobenzylamino)quinazolin-2-yl)piperi-
din-4-yl-amino)acetic acid (44).2-(1-(4-(4-Fluorobenzylamino)
quinazolin-2-yl)piperidin-4-yl-amino)acetic acid (44) was pre-
pared according to the representative procedure I. MS: ESI-MS,
m/z: 410.28 (M+1); HRMS (ESMS) calcd for C22H24FN5O2,
410.1987; found, 410.1984 (M+1). LCMS: 95.9% purity. 1H NMR:
(400 MHz, DMSO-D2O): d 1.42–1.51 (2H, m), 2.05–2.12 (2H, m),
3.07 (2H, t, J = 13.2 Hz), 3.30–3.41 (1H, m) 3.49 (2H, s), 4.56 (2H ,
br s), 4.70 (2H, s), 7.12 (2H, t, J = 8.8 Hz), 7.41 (3H, t, J = 6.8 Hz),
7.58 (1H, d, J = 8.4 Hz) 7.77 (1H, t, J = 7.6 Hz), 8.14(1H, d, J = 7.6 Hz).
4.6.1.41. 2-(1-(4-((4-Fluorobenzyl)amino)quinazolin-2-yl)piper-
idin-2-yl)acetic acid (45).2-(1-(4-((4-Fluorobenzyl)amino)quinaz-
olin-2-yl)piperidin-2-yl)acetic acid (45) was prepared according to
the representative procedure I. MS: ESI-MS, m/z: 395.23 (M+1),
LCMS: 95.8% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.27–1.41
(1H, m), 1.55–1.71 (5H, m), 2.66–2.72 (1H, m), 2.99 (1H, br s),
3.37–3,40 (1H, m), 4.52 (1H, br s), 4.71 (2H, d, J = 5.6 Hz), 5.28
(1H, br s), 7.13 (2H, t, J = 8.8 Hz), 7.27 (1H , br s), 7.42–7.46 (2H,
m), 7.48–7.52 (1H, m), 7.64–7.71 (1H, m), 8.15 (1H, d, J = 8 Hz),
9.34 (1H, br s), 12.12 (1H, br s).
4.6.1.42. N4-(4-Fluorobenzyl)quinazoline-2,4-diamine (46).N4-
(4-Fluorobenzyl)quinazoline-2,4-diamine (46) was prepared
according to the representative procedure I. MS: ESI-MS, m/z:
269 (M+1); HRMS (ESMS) calcd for C15H13FN4, 269.1197; found,
269.1197 (M+1). UPLC: 99.4% purity. 1H NMR: (400 MHz, DMSO-
d6): d 4.76 (2H, d, J = 5.2 Hz), 7.16 (2H, t, J = 8.4 Hz), 7.30 (1H, t,
J = 7.2 Hz), 7.38 (2H, d , J = 8 Hz), 7.43–7.47 (3H, m), 7.70 (1H, t,
J = 7.6 Hz), 8.23 (1H, d, J = 8.4 Hz), 9.56 (1H, t, NH).4.6.1.43. N4-(4-Fluorobenzyl)-N2-methylquinazoline-2,4-diamine
(47).N4-(4-Fluorobenzyl)-N2-methylquinazoline-2,4-diamine (47)
was prepared according to the representative procedure I. Yield:
60 mg, 65%. MS: ESI-MS, m/z: 283.21 (M+1); HRMS (ESMS) calcd
for C16H15FN4, 283.1354; found, 283.1354 (M+1). LCMS: 98.7% pur-
ity. 1H NMR: (400 MHz, DMSO-d6): d 2.89–3.07 (3H, m), 4.71–
4.79(2H, m), 7.17 (2H, t, J = 8.8 Hz), 7.41–7.47 (4H, m), 7.79 (2H,
t, J = 8 Hz), 7.89 (1H, br s), 8.33 (1H, br s).
4.6.1.44. N4-(4-Fluorobenzyl)-N2,N2-dimethylquinazoline-2,4-
diamine (48).N4-(4-Fluorobenzyl)-N2,N2-dimethylquinazoline-
2,4-diamine (48) was prepared according to the representative
procedure I. Yield: 46 mg, 53%. MS: ESI-MS, m/z: 297.22 (M+1);
HRMS (ESMS) calcd for C17H17FN4, 297.1510; found, 297.1514
(M+1). LCMS: 99.6% purity. 1H NMR: (400 MHz, CDCl3): d 3.23
(6H, s), 4.79 (2H, d, J = 5.6 Hz), 5.72 (1H, br s), 7.00–7.05 (3H, m),
7.35–7.38 (2H, m), 7.44–7.49 (3H, m).
4.6.1.45. N-(4-Fluorobenzyl)-2-(pyrrolidin-1-yl)quinazolin-4-
amine (49).N-(4-Fluorobenzyl)-2-(pyrrolidin-1-yl)quinazolin-4-
amine (49) was prepared according to the representative
procedure I. Yield: 55 mg, 50%. MS: ESI-MS, m/z: 323.27 (M+1),
LCMS: 99.3% purity. 1H NMR: (400 MHz, CDCl3): d 1.94–1.97 (4H,
m), 3.63–3.66 (4H, m), 4.78–4.79 (2H, d, J = 5.6 Hz), 5.73 (1H, t,
NH), 6.99–7.04 (3H, m), 7.35–7.39 (2H, m), 7.45 (1H, d, J = 8 Hz),
7.47–7.52 (2H, m).4.6.1.46. N-(4-Fluorobenzyl)-2-(isoindolin-2-yl)quinazolin-4-
amine hydrochloride (50).N-(4-Fluorobenzyl)-2-(isoindolin-2-
yl)quinazolin-4-amine hydrochloride (50) was prepared according
to the representative procedure I. MS: ESI-MS,m/z: 371.1(M+1). 1H
NMR (300 MHz, DMSO-d6): d 4.89 (2H, d, J = 5.7 Hz), 5.04 (4H, d,
J = 5.2 Hz), 7.22 (2H, t, J = 9.0 Hz), 7.37–7.61 (7H, br m), 7.83–7.91
(2H, br m), 8.39 (1H, d, J = 8.2 Hz), 10.23 (1H, br s), 12.08 (1H, br s).
4.6.1.47. N-(4-Fluorobenzyl)-2-(piperazin-1-yl)quinazolin-4-
amine (51).N-(4-Fluorobenzyl)-2-(piperazin-1-yl)quinazolin-4-
amine (51) was prepared according to the representative
procedure I. MS: ESI-MS, m/z: 338.15 (M+1); HRMS (ESMS) calcd
for C19H20FN5, 338.1776; found, 338.1778 (M+1). UPLC: 96% purity.
1H NMR: (400 MHz, CD3OD): d 2.81–2.88 (4H, m), 3.78–3.83 (4H,
m), 4.74 (2H, d), 7.00–7.05 (2H, m), 7.13 (1H, t, J = 6.8 Hz), 7.37–
7.40 (3H, m), 7.52–7.56 (1H, m), 7.88–7.91 (1H, m).
4.6.1.48. 2,20-(4-(4-Fluorobenzylamino)quinazolin-2-ylazanediyl)
diethanol (53).2,20-(4-(4-Fluorobenzylamino)quinazolin-2-ylaz
anediyl)diethanol (53) was prepared according to the representa-
tive procedure I. MS: ESI-MS, m/z: 357.19 (M+1), LCMS: 99.5% pur-
ity. 1H NMR: (400 MHz, DMSO-d6): d 3.50–3.64 (8H, m), 4.65 (2H,
d, J = 5.2 Hz), 7.15–7.05 (3H, m), 7.24–7.31 (1H, m), 7.38–7.41 (2H,
m), 7.51 (1H, d, J = 10.4 Hz), 8.01–8.04 (1H, m), 8.62–8.60 (1H, d,
J = 8.8 Hz).
4.6.2. Representative procedure II for the synthesis of 56–61
4.6.2.1. Synthesis of N-(4-ﬂuorobenzyl)-2-phenylquinazolin-4-
amine (60).To a stirred solution of 2-aminobenzamide (4 g,
29.4 mmol) in THF (100 mL) was slowly added benzoyl chloride
(12.4 g, 88.2 mmol). The reaction mixture was stirred at rt for 1 h
and concentrated under reduced pressure and the residue washed
with hexane then recrystallized from a mixture of acetone and
hexane, to afforded N-(2-carbamoylphenyl)benzamide (0.990 g,
15% yield).
To a stirred solution of 2(-(2-carbamoylphenyl)benzamide)
(0.12 g, 0.5 mmol) in toluene (10 mL) was added NaOMe (0.067 g,
1.25 mmol) and reﬂuxed at 110 C for 5 h. The reaction progress
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solution of NH4Cl and extracted with CH2Cl2. The organic layer was
dried over Na2SO4, ﬁltered and concentrated under reduced
pressure to afford 2-phenylquinazolin-4(3H)-one (85 mg, 77%).
The 2-phenylquinazolin-4(3H)-one) (80 mg, 0.4 mmol) was taken
up in POCl3 (4 mL) and heated in a sealed tube at 120 C for 3 h.
The reaction mixture was concentrated under reduced pressure
and co-distilled with toluene. The residue was dissolved in ethyl
acetate (50 mL) and washed with aqueous NaHCO3 (30 mL) and
with brine (30 mL). The organic layer was dried over Na2SO4,
ﬁltered and concentrated under reduced pressure. Crude product
was puriﬁed by column chromatography on (100–200 mesh) silica
gel using ethyl acetate in hexane to give 4-chloro-2-phenylquinaz-
oline (40 mg, 46%). Reaction of this chloroquinazoline with
(4-ﬂuorophenyl)methanamine (41 mg, 0.33 mmol) according to
representative procedure I afforded the ﬁnal product, N-(4-ﬂuorob-
enzyl)-2-phenylquinazolin-4-amine (45 mg, 73%). MS: ESI-MS, m/z:
330.09 (M+1), UPLC: 99.3% purity. 1H NMR: (400 MHz, DMSO-d6):
d 4.90 (2H, d, J = 4.8 Hz), 7.13–7.15 (2H, m), 7.45–7.53 (6H, m),
7.76–7.79 (2H, m), 8.29 (1H, d, J = 8 Hz), 8.42–8.45 (2H, m), 8.93
(1H, t, J = 5.6 Hz).
4.6.2.2. N-(4-Fluorobenzyl)-2-(piperidin-1-ylmethyl)quinazolin-
4-amine (56).N-(4-Fluorobenzyl)-2-(piperidin-1-ylmethyl)quinaz
olin-4-amine (56) was prepared starting from 2-aminobenzamide
and 2-(piperidin-1-yl)acetyl chloride according to representative
procedure II described for synthesis of 60. MS: ESI-MS, m/z:
351.37 (M+1), LCMS: 95.7% purity. 1H NMR (400 MHz, DMSO-d6):
d 1.25–1.34 (2H, m), 1.38–1.47 (4H, m), 2.39–2.45 (4H, m), 3.48
(2H, s), 4.74(2H, d, J = 5.6 Hz), 7.11 (2H, t, J = 8.8 Hz), 7.40–7.50
(3H, m), 7.65 (1H, d, J = 8 Hz), 7.73 (1H, t, J = 7.6 Hz), 8.22 (1H, d,
J = 8 Hz), 8.76 (1H, t, J = 5.2 Hz).
4.6.2.3. N-(4-Fluorobenzyl)quinazolin-4-amine (57).N-(4-Fluo-
robenzyl)quinazolin-4-amine (57) was prepared starting from
condensation of 2-aminobenzonitrile with 1,1-dimethoxy-N,N-
dimethylmethanamine as the initial step to representative proce-
dure II described for synthesis of 60. MS: ESI-MS, m/z: 254.16
(M+1); HRMS (ESMS) calcd for C15H12FN3, 254.1088; found,
254.1091 (M+1). LCMS: 99.6% purity. 1H NMR: (400 MHz, DMSO-
d6): d 4.77 (2H, d, J = 5.6 Hz) 7.13 (2H, t, J = 8.8 Hz), 7.38–7.42
(2H, m), 7.54 (1H, t, J = 7.2 Hz), 7.70 (1H, d, J = 8.4 Hz), 7.79 (1H,
t, J = 7.2 Hz), 8.29 (1H, d, J = 8 Hz), 8.47 (1H, s), 8.93 (1H, br s).
4.6.2.4. N-(4-Fluorobenzyl)-2-methylquinazolin-4-amine (58).N-
(4-Fluorobenzyl)-2-methylquinazolin-4-amine (58) was prepared
starting from 2-aminobenzamide and acetylchloride according to
representative procedure II described for synthesis of 60. MS: ESI-
MS, m/z: 268.21 (M+1); HRMS (ESMS) calcd for C16H14FN3,
268.1245; found, 268.1247 (M+1). LCMS: 99.5% purity. 1H NMR:
(400 MHz, DMSO-d6): d 2.43 (3H, s), 4.75 (2H, d, J = 5.6 Hz), 7.12–
7.17 (2H, m), 7.40–7.45 (3H, m), 7.59 (1H, d, J = 8.4 Hz), 7.69–7.73
(1H, m), 8.21 (1H, d, J = 8 Hz), 8.68 (1H, t, 6 Hz).
4.6.2.5. N-(4-Fluorobenzyl)-2-(triﬂuoromethyl)quinazolin-4-
amine (59).N-(4-Fluorobenzyl)-2-(triﬂuoromethyl)quinazolin-4-
amine (59) was prepared by amination of 4-chloro-2-(triﬂuoromethyl)
quinazoline according to representative procedure I. MS: ESI-MS,
m/z: 322.10 (M+1); HRMS (ESMS) calcd for C16H11F4N3,
322.0962; found, 322.0964 (M+1). LCMS: 99.5% purity. 1H NMR:
(400 MHz, DMSO-d6): d 4.77 (2H, s), 6.22 (1H, br s) 7.04 (3H, m),
7.41 (1H, dd, , J = 5.4 Hz and 3.0 Hz), 7.57 (1H, t, J = 7.2 Hz), 7.74–
7.85 (2H, m), 7.98 (1H, d, J = 8.4 Hz).
4.6.2.6. 2-Cyclohexyl-N-(4-ﬂuorobenzyl)quinazolin-4-amine
(61).2-Cyclohexyl-N-(4-ﬂuorobenzyl)quinazolin-4-amine (61)was prepared starting from 2-aminobenzamide and cyclohexane-
carbonyl chloride according to representative procedure II
described for synthesis of 60. MS: ESI-MS, m/z: 336.27 (M+1);
HRMS (ESMS) calcd for C21H22FN3, 336.1871; found, 336.1871
(M+1). LCMS: 98.7% purity. 1H NMR: (400 MHz, DMSO-d6): d
1.51–1.87 (10H, m), 2.56–2.63 (1H, m), 4.75 (2H, d, J = 5.2 Hz),
7.13 (2H, t, 8.8 Hz), 7.39–7.45 (3H, m), 7.60 (1H, d, J = 7.6 Hz),
7.70 (1H, t, J = 7.2 Hz), 8.19 (1H, d, J = 8 Hz), 8.68 (1H, t, J = 6 Hz).
4.6.3. Representative procedure III for the synthesis of 62–66
4.6.3.1. 5-Benzyl-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)pyrimi-
din-4-amine (65).A solution of 5-benzylpyrimidine-2,4(1H,3H)-
dione (0.5 g, 2.0 mmol) in POCl3 (3 mL) in a sealed tube was stirred
at 100 C for 3 h, monitoring progress by TLC. The reaction mixture
was concentrated under reduced pressure and co-distilled with
toluene. The residue was dissolved in ethyl acetate (50 mL) and
washed with aqueous NaHCO3 (30 mL) and brine (30 mL). The
organic layer was dried over Na2SO4, ﬁltered and concentrated
under reduced pressure, to afford 5-benzyl-2,4-dichloropyrimidine
(0.4 g, 68% yield).
To a pre-cooled solution of 5-benzyl-2,4-dichloropyrimidine
(0.4 g, 1.6 mmol) in THF (20 mL) in two-neck round-bottomed ﬂask
was added (4-ﬂuorophenyl)methanamine (0.315 g, 2.5 mmol) drop
wise then stirred for 20 min at rt under nitrogen atmosphere. The
reaction was monitored by TLC. The mixture was concentrated
under reduced pressure and the crude compound dissolved in
ethyl acetate and washed with NaHCO3 and brine solution. The
organic layer was dried over Na2SO4, ﬁltered and concentrated
under reduced pressure. Crude product was puriﬁed by column
chromatography on (60–120 mesh) silica gel using 20% ethyl ace-
tate in hexane to give 5-benzyl-2-chloro-N-(4-ﬂuorobenzyl)pyrim-
idin-4-amine (0.24 g, 43%).
5-Benzyl-2-chloro-N-(4-ﬂuorobenzyl)pyrimidin-4-amine (0.2 g,
0.6 mmol) in MeCN (10 mL) was treated with piperidine (0.155 g,
1.8 mmol) and K2CO3 (0.337 g, 2.7 mmol) then heated at 90 C in
a sealed tube for 16 h. The reaction mixture was quenched with
water (50 mL), concentrated to remove MeCN then extracted with
ethyl acetate (2  30 mL). The organic layer was dried over Na2SO4,
ﬁltered and concentrated under reduced pressure. Crude product
was puriﬁed by column chromatography on (60–120 mesh) silica
gel using ethyl acetate in hexane to give pure 5-Benzyl-N-(4-ﬂuo-
robenzyl)-2-(piperidin-1-yl)pyrimidin-4-amine (65) (0.140 g, 61%
yield). MS: ESI-MS, m/z: 377.29 (M+1); HRMS (ESMS) calcd for
C23H25FN4, 377.2136; found, 377.2140 (M+1). LCMS: 97.8% purity.
1H NMR: (400 MHz, DMSO-d6): d 1.33–1.42 (4H, m), 1.48–1.54 (2H,
m), 3.53–3.58 (4H, m), 3.67 (2H, s), 4.45 (2H, d, J = 5.6 Hz), 7.03–
7.07 (3H, m), 7.17–7.22 (5H, m), 7.26–7.29 (2H, m), 7.56 (1H, s).
4.6.3.2. N-(4-Fluorobenzyl)-6-methyl-2-(piperidin-1-yl)pyrimi-
din-4-amine (62).N-(4-Fluorobenzyl)-6-methyl-2-(piperidin-1-yl)
pyrimidin-4-amine (62) was prepared from 2,4-dichloro-6-meth-
ylpyrimidine according to representative procedure III described
for synthesis of 65. Yield: 200 mg, 76%. MS: ESI-MS, m/z: 301.20
(M+1); HRMS (ESMS) calcd for C17H21FN4, 301.1823; found,
301.1825 (M+1). LCMS: 98.6% purity. 1H NMR: (400 MHz, CDCl3):
d 1.50–1.65 (6H, m), 2.18 (3H, s), 3.69–3.75 (4H, m), 4.47 (2H, d,
J = 5.6 Hz), 4.74 (1H, br s), 5.51 (1H, s), 6.95–7.03 (2H, m), 7.25–
7.30 (2H, m).
4.6.3.3. N-(4-Fluorobenzyl)-5-methyl-2-(piperidin-1-yl)pyrimi-
din-4-amine (63).N-(4-Fluorobenzyl)-5-methyl-2-(piperidin-1-yl)
pyrimidin-4-amine (63) was prepared from 2,4-dichloro-5-meth-
ylpyrimidine according to representative procedure III described
for synthesis of 65. Yield: 35 mg, 51%. MS: ESI-MS, m/z: 301.22
(M+1); HRMS (ESMS) calcd for C17H21FN4, 301.1823; found,
301.1823 (M+1). LCMS: 95.4% purity. 1H NMR: (400 MHz, CDCl3):
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m), 4.63 (3H, s), 6.98–7.03 (2H, m), 7.29–7.33 (2H, m), 7.69 (1H, s).
4.6.3.4. N-(4-Fluorobenzyl)-5,6-dimethyl-2-(piperidin-1-yl)pyr-
imidin-4-amine (64).N-(4-Fluorobenzyl)-5,6-dimethyl-2-(piperid
in-1-yl)pyrimidin-4-amine (64) was prepared from 2,4-dichloro-
5,6-dimethylpyrimidine according to representative procedure III
described for synthesis of 65. Yield: 30 mg, 45%. MS: ESI-MS, m/z:
315.26 (M+1); HRMS (ESMS) calcd for C18H23FN4, 315.1980; found,
315.1981 (M+1). LCMS: 98.6% purity. 1H NMR: (400 MHz,
DMSO-d6): d 1.33–1.39 (4H, m), 1.48–1.53 (2H, m), 1.88 (3H, s),
2.09 (3H, s), 3.51–3.56 (4H, m), 4.45 (2H, d, J = 5.6 Hz), 6.95 (1H,
t, J = 6 Hz), 7.03–7.13 (2H, m), 7.29–7.35 (2H, m).
4.6.3.5. 6-Benzyl-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)pyrimi-
din-4-amine (66).6-Benzyl-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)
pyrimidin-4-amine (66) was prepared from 6-benzylpyrimidine-
2,4(1H,3H)-dione according to representative procedure III
described for synthesis of 65. MS: ESI-MS,m/z: 377.3 (M+1); HRMS
(ESMS) calcd for C23H25FN4, 377.2136; found, 377.21368 (M+1),
LCMS: 98.3% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.37–1.43
(4H, m), 1.52–1.61 (2H, m), 3.57–3.65 (6H, m), 4.35–4.39 (2H,
m), 5.50 (1H, s), 7.09–7.11 (2H, m), 7.18–7.20 (1H, m), 7.23–7.30
(6H, m), 7.35 (1H, t, NH).
4.6.3.6. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)pyrido[2,3-d]pyr-
imidin-4-amine (67).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)pyrido
[2,3-d]pyrimidin-4-amine (67) was prepared from 2-aminonicoti-
nic acid via a pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione interme-
diate according to representative procedure III described for
synthesis of 65. MS: ESI-MS, m/z: 338.29 (M+1); HRMS (ESMS)
calcd for C19H20FN5, 338.1776; found, 338.1778 (M+1). LCMS:
99% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.39–1.50 (4H, m),
1.57–1.63 (2H, m), 3.71–3.80 (4H, m), 4.61–4.65 (2H, m), 7.01–
7.07 (1H, m), 7.13 (2H, t, 8 Hz), 7.37–7.43 (2H, m), 8.39 (1H, d,
J = 7.6 Hz), 8.59–8.65 (1H, m), 8.80 (1H, br s).
4.6.3.7. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)pyrido[3,4-d]pyr-
imidin-4-amine (68).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)pyrido
[3,4-d]pyrimidin-4-amine (68) was prepared from 3-aminoisoni-
cotinic acid via a pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione inter-
mediate according to representative procedure III described for
synthesis of 65. MS: ESI-MS, m/z: 338.40 (M+1); HRMS (ESMS)
calcd for C19H20FN5, 338.1776; found, 338.1778 (M+1). LCMS:
96.6% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.41–1.47 (4H, m),
1.52–1.61 (2H, m), 3.70–3.77 (4H, m), 4.66 (2H, d, J = 4.4 Hz),
7.13 (2H, t, 8.8 Hz), 7.37–7.43 (2H, m), 7.85(1H, d, J = 5.6 Hz),
8.15 (1H, d, J = 5.2 Hz), 8.61 (1H, s), 8.82 (1H, t, NH).
4.6.3.8. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)pyrido[3,2-d]pyr-
imidin-4-amine (69).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)pyrido
[3,2-d]pyrimidin-4-amine (69) was prepared from 3-aminopico-
linic acid via a pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione interme-
diate according to representative procedure III described for
synthesis of 65. MS: ESI-MS, m/z: 338.27 (M+1); HRMS (ESMS)
calcd for C19H20FN5, 338.1776; found, 338.1779 (M+1). LCMS:
99.3% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.42–1.50 (4H, m),
1.53–1.60 (2H, m), 3.72–3.77 (4H, m), 4.61 (2H, d, J = 6 Hz), 7.11
(2H, t, J = 8.8 Hz), 7.41–7.44 (2H, m), 7.50–7.53 (1H, m), 7.60 (1H,
d, J = 8.4 Hz), 8.32 (1H, d, J = 4 Hz), 8.73 (1H, t, J = 6 Hz).
4.6.3.9. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)thieno[2,3-d]pyr-
imidin-4-amine (70).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)thieno
[2,3-d]pyrimidin-4-amine (70) was prepared from 2-aminothioph-
ene-3-carboxylic acid via a thieno[2,3-d]pyrimidine-2,4(1H,3H)-
dione intermediate according to representative procedure IIIdescribed for synthesis of 65. MS: ESI-MS, m/z: 343.26 (M+1),
LCMS: 99.1% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.38–1.44
(4H, m), 1.54–1.57 (2H, m), 3.62–3.68 (4H, m), 4.60 (2H, d,
J = 5.6 Hz), 6.96 (1H, d, J = 6 Hz), 7.13 (2H, t, J = 8.4 Hz), 7.33–7.42
(3H, m), 8.17 (1H, t, J = 5.6 Hz).
4.6.3.10. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)thieno[3,2-d]pyr-
imidin-4-amine (71).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)thieno
[3,2-d]pyrimidin-4-amine (71) was prepared from 3-aminothioph-
ene-2-carboxylic acid via a thieno[3,2-d]pyrimidine-2,4(1H,3H)-
dione intermediate according to representative procedure III
described for synthesis of 65. MS: ESI-MS, m/z: 343.22 (M+1);
HRMS (ESMS) calcd for C18H19FN4S, 343.1387; found, 343.1393
(M+1). LCMS: 98.2% purity. 1H NMR: (400 MHz, DMSO-d6): d
1.39–1.45 (4H, m), 1.54–1.59 (2H, m), 3.62–3.69 (4H, m), 4.59
(2H, d, J = 5.6 Hz), 7.04 (1H, d, J = 5.2 Hz), 7.12 (2H, t, J = 9.2 Hz),
7.36–7.40 (2H, m), 7.87 (1H, d, J = 5.2 Hz), 8.08 (1H, br s).
4.6.3.11. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)-7H-pyrrolo[2,3-
d]pyrimidin-4-amine (72).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)-
7H-pyrrolo[2,3-d]pyrimidin-4-amine (72) was prepared from
1H-pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione according to repre-
sentative procedure III described for synthesis of 65. MS: ESI-MS,
m/z: 326.17 (M+1), LCMS: 99.5% purity. 1H NMR: (400 MHz,
DMSO-d6): d 1.39–1.45 (4H, m), 1.52–1.58 (2H, m), 3.59–3.64
(4H, m), 4.58 (2H, d, J = 5.2 Hz), 6.31 (1H, s), 6.66 (1H, s), 7.11
(2H, t, J = 8.8 Hz), 7.37 (2H, t, J = 6 Hz), 7.66 (1H, br s), 10.77 (1H, s).
4.6.3.12. N-(4-Fluorobenzyl)-7-methyl-2-(piperidin-1-yl)-7H-
pyrrolo[2,3-d]pyrimidin-4-amine (73).N-(4-Fluorobenzyl)-7-
methyl-2-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (73)
was prepared by a standard methylation of N-(4-ﬂuorobenzyl)-2-
(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (72) with
methyl iodide in K2CO3 and MeCN. MS: ESI-MS, m/z: 340.20
(M+1), LCMS: 98.8% purity. 1H NMR: (400 MHz, DMSO-d6): d
1.44–1.48 (4H, m), 1.53–1.57 (2H, m), 3.51 (3H, s), 3.64–3.67
(4H, m), 4.59 (2H, d, J = 6 Hz), 6.33 (1H, d, J = 3.6 Hz), 6.70 (1H, d,
J = 3.6 Hz), 7.10 (2H, t, J = 8.8 Hz), 7.35–7.38 (2H, m), 7.65 (1H, t,
J = 6 Hz).
4.6.3.13. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)-9H-purin-6-am
ine (74).N-(4-Fluorobenzyl)-2-(piperidin-1-yl)-9H-purin-6-amine
(74) was prepared from 2,6-dichloro-9H-purine according to repre-
sentative procedure I. MS: ESI-MS,m/z: 327.28 (M+1), LCMS: 99.9%
purity. 1H NMR: (400 MHz, DMSO-d6): d 1.40–1.47 (4H, m), 1.52–
1.58 (2H, m), 3.61–3.67 (4H, m), 4.55 (2H, s), 7.07–7.15 (2H, m),
7.37–7.40 (2H, m), 7.68 (1H, s), 7.93 (1H, br s), 12.18 (1H, s).
4.6.3.14. N-(4-Fluorobenzyl)-9-methyl-2-(piperidin-1-yl)-9H-
purin-6-amine (75).N-(4-Fluorobenzyl)-9-methyl-2-(piperidin-1-
yl)-9H-purin-6-amine (75) was prepared by direct methylation of
N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)-9H-purin-6-amine (74) with
methyl iodine in K2CO3/MeCN. MS: ESI-MS, m/z: 341.18 (M+1),
LCMS: 99.4% purity.1H NMR: (400 MHz, DMSO-d6): d 1.40–1.49
(4H, m), 1.53–1.59 (2H, m), 3.54 (3H, s), 3.62–3.69 (4H, m), 4.55
(2H, br s), 7.07–7.11 (2H, m), 7.35–7.39 (2H, m),7.69(1H, s), 7.87
(1H, br s).4.6.3.15. 5-Fluoro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)quinaz-
olin-4-amine (76).5-Fluoro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-
yl)quinazolin-4-amine (76) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 355.23 (M+1), LCMS:
99.8% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.38–1.42 (4H, m),
1.52–1.61 (2H, m), 3.67–3.71 (4H, m), 4.63 (2H, d, J = 5.6 Hz),
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7.37–7.46 (3H, m), 8.00–8.09 (1H, m).4.6.3.16. N-(4-Fluorobenzyl)-8-nitro-2-(piperidin-1-yl)quinazo-
lin-4-amine (77).N-(4-Fluorobenzyl)-8-nitro-2-(piperidin-1-yl)
quinazolin-4-amine (77) was prepared according to the represen-
tative procedure I. MS: ESI-MS, m/z: 382.41 (M+1), LCMS: 96.7%
purity. 1H NMR: (400 MHz, CDCl3): d 1.53–1.59 (4H, m), 1.65–
1.73 (2H, m), 3.87–3.95 (4H, m), 4.75 (2H, d, J = 5.2 Hz), 5.77 (1H,
t, NH),6.94 (1H, t, J = 8 Hz), 7.03 (2H, t, J = 8.8 Hz), 7.35–7.41 (2H,
m), 7.60 (1H, d, J = 7.6 Hz), 7.90 (1H, dd, J = 7.2 Hz).4.6.3.17. 5-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)quinaz-
olin-4-amine (78).5-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)
quinazolin-4-amine (78) was prepared according to the represen-
tative procedure I. MS: ESI-MS, m/z: 371.23 (M+1), LCMS: 99.7%
purity. 1H NMR: (400 MHz, CDCl3): d 1.52–1.58 (4H, m) 1.62–
1.64 (2H, m), 3.78–3.80 (4H, m), 4.73 (2H, d, J = 5.2 Hz), 6.97 (1H,
dd, J = 4.4 Hz), 7.00–7.05 (2H, m), 7.27–7.34 (2H, m), 7.36–7.38
(2H, m), 7.77 (1H, t, NH).
4.6.3.18. 6-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)quinaz-
olin-4-amine (79).6-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)
quinazolin-4-amine (79) was prepared according to the represen-
tative procedure I. MS: ESI-MS, m/z: 371.20 (M+1), LCMS: 99.9%
purity. 1H NMR: (400 MHz, CDCl3): d 1.54–1.61 (4H, m), 1.62–
1.66 (2H, m), 3.82–3.85 (4H, m), 4.74 (2H, d, J = 5.6 Hz), 5.59 (1H,
t, NH), 7.01–7.06 (2H, m), 7.34–7.38 (3H, m), 7.40 (2H, br s).
4.6.3.19. 7-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)quinaz-
olin-4-amine (80).7-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)
quinazolin-4-amine (80) was prepared according to the represen-
tative procedure I. MS: ESI-MS, m/z: 371.23 (M+1), LCMS: 99.3%
purity. 1H NMR: (400 MHz, CDCl3): d 1.51–1.61 (4H, m), 1.62–
1.67 (2H, m), 3.83–3.86 (4H, m), 4.74 (2H, d, J = 5.6 Hz), 5.63(1H,
br s, NH), 6.94 (1H, dd, J = 6.8 Hz) , 7.00–7.05 (2H, m), 7.33–7.37
(3H, m), 7.43 (1H, d, J = 2 Hz).
4.6.3.20. 8-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)quinaz-
olin-4-amine (81).8-Chloro-N-(4-ﬂuorobenzyl)-2-(piperidin-1-yl)
quinazolin-4-amine (81) was prepared according to the represen-
tative procedure I. MS: ESI-MS, m/z: 371.23 (M+1), LCMS: 99.8%
purity. 1H NMR: (400 MHz, CDCl3): d 1.56–1.61 (4H, m), 1.64–
1.67 (2H, m), 3.89–3.91 (4H, m), 4.76 (2H, d, J = 5.2 Hz), 5.70 (1H,
br s, NH), 6.90 (1H, t, J = 8 Hz), 7.03 (2H, m), 7.33–7.37 (3H, m),
7.61 (1H, d, J = 6.8 Hz).
4.6.3.21. N-(4-Fluorobenzyl)-5-methyl-2-(piperidin-1-yl)qui-
nazolin-4-amine (82).N-(4-Fluorobenzyl)-5-methyl-2-(piperidin-
1-yl)quinazolin-4-amine (82) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 351.26 (M+1), LCMS:
98.9% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.31–1.42 (4H, m),
1.52–1.61 (2H, m), 2.79 (3H, s), 3.63–3.71 (4H, m), 4.65 (2H, d,
J = 5.2 Hz), 6.81 (1H, d, J = 7.2 Hz), 7.07–7.13 (3H, m), 7.28–7.35
(2H, m), 7.39–7.43 (2H, m).
4.6.3.22. N-(4-Fluorobenzyl)-6-methyl-2-(piperidin-1-yl)quinaz
olin-4-amine (83).N-(4-Fluorobenzyl)-6-methyl-2-(piperidin-1-
yl)quinazolin-4-amine (83) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 351.21 (M+1); HRMS
(ESMS) calcd for C21H23FN4, 351.1980; found, 351.1983 (M+1).
LCMS: 99.1% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.39–1.46(4H, m) 1.55–1.61 (2H, m), 2.33 (3H, s), 3.66–3.72 (4H, m), 4.63
(2H, d, J = 5.6 Hz), 7.09–7.14 (2H, m), 7.16 (1H, d, J = 8.8 Hz), 7.32
(1H, d, J = 8.4 Hz), 7.38–7.41 (2H, m), 7.80 (1H, s), 8.41 (1H, t,
J = 5.6 Hz).4.6.3.23. N-(4-Fuorobenzyl)-6-methoxy-2-(piperidin-1-yl)qui-
nazolin-4-amine (84).N-(4-Fuorobenzyl)-6-methoxy-2-(piperi-
din-1-yl)quinazolin-4-amine (84) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 367.27 (M+1), LCMS:
97.1% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.39–1.42 (4H, m),
1.55–1.62 (2H, m), 3.67–3.71 (4H, m), 3.79 (3H, s), 4.66
(2H, d, J = 5.6 Hz), 7.10–7.17 (3H, m), 7.21 (1H, d, J = 8.8 Hz),
7.39–7.42 (2H, m), 7.49–7.50 (1H, d, J = 2.8 Hz), 8.41 (1H, t,
J = 5.6 Hz, NH).4.6.3.24. N-(4-Fluorobenzyl)-7-methoxy-2-(piperidin-1-yl)qui-
nazolin-4-amine (85).N-(4-Fluorobenzyl)-7-methoxy-2-(piperi-
din-1-yl)quinazolin-4-amine (85) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 367.27 (M+1), LCMS:
99.9% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.39–1.49 (4H, m),
1.53–1.61 (2H, m), 3.70–3.73 (4H, m), 3.8 (3H, s), 4.63 (2H, d, J=
5.6 Hz), 6.95 (1H, t, J = 7.6 Hz), 7.01 (1H, d, J = 6.8 Hz), 7.09–7.14
(2H, m), 7.37–7.40 (2H, m), 7.55 (1H, d, J = 6.8 Hz), 8.42 (1H, dd,
J = 6 Hz, NH).
4.6.3.25. N-(4-Fluorobenzyl)-8-methoxy-2-(piperidin-1-yl)qui-
nazolin-4-amine (86).N-(4-Fluorobenzyl)-8-methoxy-2-(piperi-
din-1-yl)quinazolin-4-amine (86) was prepared according to the
representative procedure I. MS: ESI-MS, m/z: 367.25 (M+1), LCMS:
99.9% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.47–1.49 (4H, m),
1.52–1.61 (2H, m), 3.65–3.73 (4H, m), 3.81 (3H, s), 4.62 (2H, d,
J = 6 Hz), 6.93–7.01 (2H, m), 7.09–7.15 (2H, m), 7.37–7.40 (2H,
m), 7.55 (1H, dd, J = 6.8 Hz) 8.42 (1H, t , J = 5.6 Hz, NH).
N-(4-Fluorobenzyl)-6,7-dimethoxy-2-(piperidin-1-yl)quinazolin-
4-amine hydrochloride (87) was prepared according to the repre-
sentative procedure I. MS: ESI-MS, m/z: 397.2 (M+1); LCMS: 98.6%
purity. 1H NMR(400MHz, DMSO-d6): d 1.70–1.49 (6H, br m),
3.81–3.73 (4H, br m), 3.86 (3H, s), 3.89 (3H, s), 4.75 (2H,
d, J = 5.6 Hz), 7.18 (2H, t, J = 8.9 Hz), 7.32 (1H, s), 7.49–7.40
(2H, br m), 7.81 (1H, s), 9.84 (1H, br s), 11.73 (1H, br s).
4.6.3.26. N-(4-Fluorobenzyl)-2-(piperidin-1-yl)quinolin-4-ami
ne (88).A mixture of 2,4-dichloroquinoline (0.3 g, 1.5 mmol) and
piperidine (3 mL) was heated at 75 C in a sealed vial for 1.5 h.
The mixture was then concentrated under reduced pressure, dis-
solved in ethyl acetate (40 mL) and washed with water (20 mL)
and with brine (20 mL). The organic layer was dried over Na2SO4,
ﬁltered and concentrated under reduced pressure. The crude prod-
uct was puriﬁed by column chromatography using ethyl acetate in
hexane to give 4-chloro-2-(piperidin-1-yl)quinoline (0.207 g,
55.3%). To a solution of this product (0.15 g, 0.6 mmol) and (4-ﬂuo-
rophenyl)methanamine (91.2 mg, 0.7 mmol) in toluene (5 mL) was
added Pd2(dba)3 (27.8 mg, 0.03 mmol), BINAP (37 mg, 0.06 mmol)
and t-BuONa (116.8 mg, 1.21 mmol) under nitrogen atmosphere.
The reaction mixture was reﬂuxed for 16 h then ﬁltered through
a pad of Celite, rinsing with ethyl acetate. The ﬁltrate was dried
over Na2SO4, ﬁltered and concentrated under reduced pressure.
The crude product was puriﬁed by column chromatography to
afford product (62 mg, 30.3% yield). MS: ESI-MS, m/z: 336.19
(M+1), LCMS: 99.1% purity. 1H NMR: (400 MHz, DMSO-d6): d
1.41–1.44 (4H, m), 1.52–1.57 (2H, m), 3.46–3.53 (4H, m), 4.50
(2H, d, J = 5.6 Hz), 5.86 (1H, s), 7.05–7.16 (3H, m), 7.37 (2H, t,
J = 8 Hz), 7.41–7.45 (3H, m), 7.98 (1H, d, J = 8.4 Hz).
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mino)ethanol (89).2-(4-Fluorophenyl)-2-(2-(piperidin-1-yl)quin-
olin-4-ylamino)ethanol (89) was prepared according to procedure
described for 88 above but employing 2-amino-2-(4-ﬂuoro-
phenyl)ethanol for amination. MS: ESI-MS, m/z: 366.22 (M+1),
LCMS: 99.1% purity. 1H NMR: (400 MHz, DMSO-d6): d 1.35–1.42
(4H, m), 1.50–1.55 (2H, m), 3.37–3.49 (4H, m), 3.67–3.73 (1H,
m), 3.78–3.84 (1H, m), 4.67 (1H, t, J = 6.4 Hz), 5.09 (1H, t,
J = 6 Hz), 5.74 (1H, s), 6.78 (1H, d, J = 6 Hz), 7.10–7.15 (3H, m),
7.35–7.42 (2H, m), 7.48–7.50 (2H, m), 8.10 (1H, d, J = 8 Hz).
4.6.3.28. 2-(4-Fluorophenyl)-2-(2-(piperidin-1-yl)quinolin-4-yla
mino)acetic acid (90).2-(4-Fluorophenyl)-2-(2-(piperidin-1-yl)
quinolin-4-ylamino)acetic acid (90) was prepared according to
procedure described for 88 above but employing 2-amino-2-(4-
ﬂuorophenyl)acetic acid for amination. MS: ESI-MS, m/z: 380.18
(M+1), LCMS: 99.7% purity. 1H NMR: (400 MHz, DMSO-d6+TFA): d
1.56–1.59 (4H, m), 1.61–1.64 (2H, m), 3.62–3.68 (4H, m), 5.91
(1H, d, J = 7.2 Hz), 5.97 (1H, s), 7.18 (2H, t, J = 8.8 Hz), 7.43 (1H, t,
J = 7.6 Hz), 7.63–7.68 (2H, m), 7.71 (1H, d, J = 7.2 Hz), 7.81 (1H, d,
J = 8.4 Hz), 8.27 (1H, d, J = 7.2 Hz,), 8.37 (1H, d, J = 8 Hz), 11.52
(1H, s).4.6.3.29. N-(4-Fluorobenzyl)-5-(piperidin-1-yl)pyrazolo[1,5-a]
pyrimidin-7-amine (94).N-(4-Fluorobenzyl)-5-(piperidin-1-yl)
pyrazolo[1,5-a]pyrimidin-7-amine (94) was prepared from 5,7-
dichloropyrazolo[1,5-a]pyrimidine (93: X = C, Y = N)11 according
to representative procedure I with 110 C and 180 C as respective
temperature conditions for each reaction step. MS: ESI-MS, m/z:
326.24 (M+1); HRMS (ESMS) calcd for C18H20FN5, 326.1776; found,
326.1779 (M+1). LCMS: 99.7% purity. 1H NMR: (400 MHz, DMSO-
d6): d 1.42–1.46 (4H, m), 1.54–1.57 (2H, m), 3.46–3.50 (4H, m),
4.53 (2H, d, J = 6.4 Hz), 5.50 (1H, s), 5.87 (1H, d, J = 1.6 Hz), 7.14
(2H, t, J = 8.8 Hz), 7.44–7.47(2H, m), 7.77 (1H, d, J = 1.6 Hz), 7.96
(1H, t, J = 6.4 Hz).4.6.3.30. N-(4-Fluorobenzyl)-5-(piperidin-1-yl)-[1,2,4]triazolo
[1,5-a]pyrimidin-7-amine (95).N-(4-Fluorobenzyl)-5-(piperidin-
1-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (95) was prepared
from 5,7-dichloro-[1,2,4]triazolo[1,5-a]pyrimidine (93: X = N,
Y = N)11 according to representative procedure I with 110 C and
180 C as respective temperature conditions for each reaction
step. MS: ESI-MS, m/z: 327.28 (M+1); HRMS (ESMS) calcd for
C17H19FN6, 327.1728; found, 327.1730 (M+1). LCMS: 98.7% purity.
1H NMR: (400 MHz, DMSO-d6): d 1.43–1.47 (4H, m), 1.54–1.59
(2H, m), 3.54–3.58 (4H, m), 4.55 (2H, d, J = 6 Hz), 5.63 (1H, s),
7.15 (2H, t, 8.4 Hz), 7.44–7.47 (2H, m), 8.08 (1H, s), 8.21 (1H, t,
J = 6 Hz).4.6.3.31. 1-(4-Fluorobenzyl)-4-(piperidin-1-yl)-1H-imidazo[4,5-
c]quinoline (103).1-(4-Fluorobenzyl)-4-(piperidin-1-yl)-1H-imi-
dazo[4,5-c]quinoline (103) was prepared from 3-nitroquinolin-4-ol
(96) in 25 mg quantity according to literature12 procedure. MS:
ESI-MS, m/z: 361.20 (M+1); HRMS (ESMS) calcd for C22H21FN4,
361.1823; found, 361.1825 (M+1). LCMS: 98.9% purity. 1H NMR:
(300 MHz, DMSO-d6): d 1.73–1.86 (6H, m), 4.33–4.48 (4H, m),
6.01 (2H, s), 7.17–7.21 (2H, m), 7.21–7.23 (2H, m), 7.40 (1H, t,
J = 7.9 Hz), 7.66 (1H, t, J = 7.9 Hz), 8.0 (1H, d, J = 8.3 Hz), 8.08
(1H, d, J = 8.3 Hz), 8.69 (1H, s).
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